

Medizinische Klinik 3 –
Rheumatologie, Immunologie und
Onkologie
und Institut für Klinische Immunologie
Friedrich-Alexander Universität Erlangen-
Nürnberg

Prof. Dr. med. Dr. h. c. mult. J. R. Kalden
Direktor emeritus

Present address: Division of Molecular Immunology
Nikolaus-Fiebiger Zentrum
Glückstraße 6
D-91054 Erlangen
Fon: +49 9131 85 29315
Email: Joachim.kalden@uk-erlangen.de

Private address: Loewenichstrasse 19
D-91054 Erlangen

Birth date: November 23, 1937

Birth place: Marburg, Germany

Degrees:

1966 MD, University of Tübingen, Germany
1973 Habilitation (PD), Venia legendi for Clinical Immunology and Internal Medicine,
Department of Internal Medicine. Medical School Hannover, Germany
1977 Appointment as Professor of Internal Medicine and Director of the Department of
Internal Medicine III and the Institute for Clinical Immunology, Medical Faculty,
University Erlangen, Germany

Positions held:

1967 - 1970 Research Fellow at the Department of Therapeutics, University of Edinburgh and the
Medical Research Council's Clinical Endocrinology Unit, University of Edinburgh,
Scotland (NATO Research Fellowship) including repeated visits at the NIH Bethesda,
Washington/USA
1970 - 1973 Assistant in the Department for Internal Medicine, Medical School Hannover, Germany
1973 Specialization for Internal Medicine
1974 - 1976 Consultant Physician at the Department for Internal Medicine, Clinical Immunology
and Rheumatology, Medical School Hannover, Germany
1977 - 2006 Director, Department of Internal Medicine III and Institute for Clinical Immunology,
Medical Faculty, University Erlangen, Germany
2006 Director emeritus, Department of internal Medicine II and Institute for Clinical
Immunology, Medical Faculty, University Erlangen-Nürnberg, German
since 2006 Member of the Division for Molecular Immunology, Nikolaus-Fiebiger-Center,
Glueckstrasse 6, 91054 Erlangen

Teaching:

1970 - 1977 Medical School Hannover, Germany
1977 - 2006 Medical School Erlangen, Germany

Memberships in national and international scientific committees:

1982 - 1991 Member of the Senatskommission for Cancer Research, German Research Foundation "Deutsche Forschungsgemeinschaft"
1983 - 1990 President of the Gesellschaft für Immunologie, Co-Chairman of the organizing Committee for the 7th International Congress for Immunology, Berlin 1989
1986 - 1992 Chairman of the WHO/IUIS Standardization Committee (International Union of Immunological Societies)
1992 - 1996 Vice-Chairman of the WHO/IUIS Standardization Committee
1986 - 1992 Member of the Scientific Board "Analytica", München
1987 - 1996 Member of the Scientific Board of the Paul-Ehrlich-Institut Frankfurt/Main
1986 - 1994 Member "Board of Trustees" Deutsches Rheumaforschungszentrum, Berlin, and Member of the Founding Committee of the "Deutsches Rheumaforschungszentrum", Berlin
1994 - 2003 President of the "Board of Trustees" Deutsches Rheumaforschungszentrum, Berlin
1989 - 1998 Chairman of the "International Scientific Committee" of the German Cancer Research Center, Heidelberg (DKFZ)
1991 - 1997 Member "Kuratorium Sandoz Foundation for Therapeutic Research"
1991 - 2016 Member and later Chairman of the GlaxoSmithKline Stiftung
1992 - 1995 Member "Scientific Board of the Bernhard-Nocht-Institute for Tropical Medicine", Hamburg
1992 - 1998 Council Member of the International Union of Immunological Societies (IUIS)
1993 - 2008 Member of the Board of Trustees of the Paul Ehrlich Society (Prestigious Paul Ehrlich Award for Medicine)
1993 - 1994 President of the Deutsche Gesellschaft for Rheumatologie
1994 - 2010 Member of the Board of Trustees of the Carol Nachman Award in Wiesbaden
1999 - 2010 Chairman of the Board of Trustees of the Carol Nachman Award in Wiesbaden
2010 - present Honorary President of the Board of Trustees of the Carol Nachman Award in Wiesbaden (most prestigious award in Rheumatology)
1993 - 1995 Member of the Abstract Committee of American College of Rheumatology (ACR)
1993 Member of the ACR Annual Meeting Planning Committee: International Relations
1996 - 1999 Member of the Scientific Advisory Board of the Bundesgesundheitsforschungsrat, BMBF (German Ministry for Science and Technology)
1997 - 2001 Member of the Scientific Board, Forschungsinstitut Borstel
2001 - 2003 Chairman of the Scientific Board, Forschungsinstitut Borstel
1997 - 1999 Member of the Presidential Committee for Clinical Research, Max-Planck Society
1997 - 1999 Chairman of the Standing Committee for Clinical Trials of the European League Against Rheumatism (EULAR)
1997 - 2003 Chairman of the Scientific Advisory Board: Interdisciplinary Center for Clinical Research, University Münster
1999 Member of a delegation of the German Federal Republic Government to explore scientific cooperation programmes with the Polish Academy of Science, the Polish Society for Rheumatology and the Polish Society for Immunology
1999 - 2003 Member of the Board of Trustees, Wilhelm-Sander Stiftung, Munich
2000 - 2005 Chairman of the Association of the Interdisciplinary Centers for Clinical Research in Germany

1999 - 2001	President Elect of EULAR
2001 - 2003	President of EULAR
2003 - 2005	Past President of EULAR
2005 - 2014	Member of the Scientific Advisory Board (Bundesgesundheitsforschungsrat, BMFT German Ministry for Science and Technology)
2003 - present	Member of the German Academy of Science Leopoldina, Chairman of the Section Internal Medicine (2012-2016 Member of the Senate)
2006 - 2012	Member of the Advisory Board, Center for Immunodeficiencies, University of Freiburg
2006 - present	Member of the International Advisory Board of the Hannover Biomedical Research School, Medizinische Hochschule Hannover
2006 - present	Member of the Organizing Committee of the Autumn School of the German Society for Immunology
2006 - 2012	Member of the International Advisory Board of the Leeds Institute of Molecular Medicine, University of Leeds and the Leeds Musculoskeletal Biomedical Research Unit
2008 - present	Member of the Founding Committee together with Prof. Reinhard Andreesen and Prof. Daniela Männel, both University Regensburg, of the Bayerisches Immuntherapie-Netzwerk

Memberships in national and international scientific societies:

01. - British Society for Immunology
02. - American Association for Immunology
03. - New York Academy of Science
04. - American College of Rheumatology
05. - Deutsche Gesellschaft für Innere Medizin,
06. - Deutsche Gesellschaft für Rheumatologie
07. - Deutsche Gesellschaft für Immunologie
08. - Gesellschaft Fortschritte auf dem Gebiet der Medizin
09. - International Interferon Society
10. - Deutsche Gesellschaft der Freunde des Weizmann Instituts
11. - Henry Kunkel Society

Advisory activities for medical faculties and medical schools:

1997	Consultant for the Ministry for Science (Saxonia) regarding the privatization of the Medical School Leipzig
2000	Consultant for the Medical Faculty Bonn, regarding the development of a specific clinical-scientific profile
2001	Advisor of the Medical Faculty Mainz regarding the re-organization of the Medical School associated with the definition of special focusses in clinical and basic research activities

Memberships in Advisory/Editorial Boards:

- Editor Rheumatology International
- Journal of Clinical and Experimental Immunology
- Journal of Clinical Chemistry and Biochemistry
- Immunobiology
- Journal of Laboratory and Clinical Immunology
- Clinical and Experimental Rheumatology
- Rheumatology Review

- Lupus Journal
- Molecular Medicine
- Scandinavian Journal of Immunology
- Arthritis and Rheumatism
- Therapiehandbuch (Section Editor)
- Qualitätssicherung in der Rheumatologie
- Rationelle Diagnostik und Therapie in der Inneren Medizin (Section Editor: Rheumatology and Immunology)
- Acta Reumatológica Portuguesa
- Japan Journal of Rheumatology
- Autoimmunity Reviews
- International Journal of Advances in Rheumatology
- Clinical Rheumatology
- ILAR Journal of Rheumatology
- Journal of Clinical Research
- Future Rheumatology
- Japan College of Rheumatology: Modern Rheumatology
- International Journal of Rheumatic Diseases

Advisory and review activities:

- DFG (Deutsche Forschungsgemeinschaft)
- Volkswagen Foundation
- BMBF (Ministry for Science and Technology)
- Deutscher Wissenschaftsrat
- Deutsches Krebsforschungszentrum
- Swiss National Fonds
- Österreichischer National Fonds
- Sander Foundation
- Dr. M. Scheel-Foundation
- The Welcome Trust
- Irish National Fund
- Dutch Arthritis Foundation
- Human Frontier Science Program
- German-Israeli Foundation
- British Arthritis Foundation
- Swedish Medical Council
- Karolinska Institutet, Stockholm, Sweden

Awards and honors:

1976	Georg Zimmerman Award for Cancer Research, Medical School Hannover
1995	The Ninth Autoimmunity Day, in honor of Prof. J. R. Kalden Israel Society of Immunology and Sackler Faculty of Medicine, Tel Aviv University
1996	Kare Berglund Lecture, University Lund, Sweden
1997	Dr. Franziscus-Blondel-Medaille, Aachen
1998	Honorary doctorate of the Medical Faculty Charité Berlin
2003	Master of the American College of Rheumatology (ACR)
2005	Honorary doctorate of the Medical Faculty Lund, Sweden
2005	International Rheumatology Award of the Japanese College for Rheumatology
2006	AESKU prize for Life Contribution to Autoimmunity, Sorrento, Italy
2007	EULAR Meritorious Award, Barcelona, Spain

2014	Honorary doctorate of the Medical School Hannover, Germany
2013	Carol Nachman Medal Award in Wiesbaden, Germany
1996	Honorary member of the Romanian Society for Rheumatology
2002	Honorary member of the German Society for Immunology
2003	Honorary member of the Austrian Society for Rheumatology
2004	Honorary member of the Germany Society for Rheumatology
2005	Honorary membership of the European League Against Rheumatism (EULAR)
2006	Honorary Member of the Czech Society for Rheumatology
2007	Honorary member of the Association of Rheumatologists of Russia
2008	Honorary ambassador of the Societas Rheumatologica Europea
2009	Honorary member of the Slovenian Society for Rheumatology
1996	Honorary speaker, 5th International Symposium of Japan Rheumatism Foundation
1997	Visiting Professor, Mc Gill University, Montreal
2002	Visiting Professor of the Department of Rheumatology of the Second Shanghai Medical University
2004	The Caposy Langsteiner Lecture of Rheumatology, Vienna General Hospital, Medical University Vienna
2007	Visiting Professor at the Kennedy Institute for Rheumatology, Imperial College London
2007	Albrecht Hasinger Lecture, Deutsches Rheumaforschungszentrum Berlin
1996	Verdienstkreuz am Bande der Bundesrepublik Deutschland (Federal Cross of Merit on ribbon by the Federal Republic of Germany)
1998	Member of the Bayerische Akademie der Wissenschaften
1999	Bayerischer Verdienstorden, München
2002 - present	Member of the National Academy Leopoldina, Halle/Germany

International educational activities

1988 - 1999	Faculty member of various IUIS/EFIS summer schools in Romania, Lithuania, Estonia, Latvia and Poland
1995 – present	Initiation of an Exchange Programme for young rheumatologists between ACR and EULAR (together with P. Lipsky, Dallas/Washington)
2001	Organisation of a forum for young rheumatologists from the APLAR region in the Annual EULAR Conference in Prague
2002	Within the frame of EULAR co-responsibility and co-organization of the EULAR Postgraduate Course in 2002 in Budapest
2002	Development of a Graduate College for young Polish immunologists/rheumatologists (together with H.-M. Jäck, University of Erlangen-Nürnberg)
2003 - 2009	Co-chairman together with Stefano Bombardieri, Pisa of the bi-annual EULAR Course on Systemic Lupus Erythematosus in Italy

Activities within the University of Erlangen-Nuremberg

1987 – 1996	Successful implementation of two Max-Plank Clinical Research Groups at the Department of Internal Medicine III (Group I: Rheumatology/Prof. F. Emmrich, Group II: Cell-Matrix Interaction/Prof. K. von der Mark)
1992	Initiator (together with Prof. M. Röllinghoff) and speaker of a specific Research Grant


(SFB 263 of the German Research Foundation): Immunologic Mechanisms in Infection, Inflammation and Autoimmunity
1996 Initiator (together with Prof. M. Röllinghoff) and speaker of the Interdisciplinary Center for Clinical Research. Inflammatory processes: pathogenesis, diagnostics and therapies
1998 - 2005 Member of the Senat of the Friedrich-Alexander University Erlangen-Nuremberg
2007 - present Member of the Forschungsstiftung Medizin at the University Hospital Erlangen

Organization and co-organization of numerous national and international scientific workshops and congresses related to rheumatology/immunology.

More than 600 publications in national and international peer-reviewed journals

More than 40 text book contributions or editorial activities

Erlangen


Prof. Dr. med. Dr. h.c. mult. Joachim R. Kalden

Publications

A) In scientific journals since 1968

1. Kavanaugh, A., C. E. Antoni, D. D. Gladman, S. Wassenberg, B. Zhou, A. Beutler, G. Keenan, G. Burmester, D. E. Furst, M. Weisman, J. R. Kalden, J. Smolen, and D. van der Heijde. 2006. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): Results of radiographic analyses after 1 year. *Ann Rheum Dis*.
2. Rech, J., F. Fuchs, S. Kallert, A. J. Hueber, C. Requadt, B. Manger, J. R. Kalden, K. Amann, R. Strauss, and H. Schulze-Koops. 2006. Plasmapheresis therapy in an elderly patient with rapidly progressive Henoch-Schonlein purpura with disseminated organ involvement. *Clin Rheumatol*:1-3.
3. Hueber, A. J., F. G. Matzkies, M. Rahmeh, B. Manger, J. R. Kalden, and T. Nagel. 2006. CTLA-4 lacking the cytoplasmic domain costimulates IL-2 production in T-cell hybridomas. *Immunol Cell Biol* 84:51-58.
4. Gaip, U. S., A. Kuhn, A. Sheriff, L. E. Munoz, S. Franz, R. E. Voll, J. R. Kalden, and M. Herrmann. 2006. Clearance of apoptotic cells in human SLE. *Curr Dir Autoimmun* 9:173-187.
5. Distler, J. H., A. Jungel, D. Caretto, U. Schulze-Horsel, O. Kowal-Bielecka, R. E. Gay, B. A. Michel, U. Muller-Ladner, J. R. Kalden, S. Gay, and O. Distler. 2006. Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells. *Arthritis Rheum* 54:214-225.
6. Schlenk, J., H. M. Lorenz, J. P. Haas, M. Herrmann, G. Hohenberger, J. R. Kalden, M. Rollinghoff, and H. U. Beuscher. 2005. Extravasation into synovial tissue induces CCL20 mRNA expression in polymorphonuclear neutrophils of patients with rheumatoid arthritis. *J Rheumatol* 32:2291-2298.
7. Blank, N., M. Schiller, C. Gabler, J. R. Kalden, and H. M. Lorenz. 2005. Inhibition of sphingolipid synthesis impairs cellular activation, cytokine production and proliferation in human lymphocytes. *Biochem Pharmacol* 71:126-135.
8. Dodeller, F., A. Skapenko, J. R. Kalden, P. E. Lipsky, and H. Schulze-Koops. 2005. The p38 mitogen-activated protein kinase regulates effector functions of primary human CD4 T cells. *Eur J Immunol* 35:3631-3642.
9. Distler, J. H., D. S. Pisetsky, L. C. Huber, J. R. Kalden, S. Gay, and O. Distler. 2005. Microparticles as regulators of inflammation: novel players of cellular crosstalk in the rheumatic diseases. *Arthritis Rheum* 52:3337-3348.
10. Furst, D. E., F. C. Breedveld, J. R. Kalden, J. S. Smolen, G. R. Burmester, J. W. Bijlsma, M. Dougados, P. Emery, E. C. Keystone, L. Klareskog, and P. J. Mease. 2005. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. *Ann Rheum Dis* 64 Suppl 4:iv2-14.
11. Skapenko, A., J. R. Kalden, P. E. Lipsky, and H. Schulze-Koops. 2005. The IL-4 receptor alpha-chain-binding cytokines, IL-4 and IL-13, induce forkhead box P3-expressing CD25+CD4+ regulatory T cells from CD25-CD4+ precursors. *J Immunol* 175:6107-6116.

12. Lorenz, H. M., M. Grunke, J. Wendler, P. A. Heinzl, and J. R. Kalden. 2005. Safety of 15-deoxyspergualin in the treatment of glomerulonephritis associated with active systemic lupus erythematosus. *Ann Rheum Dis* 64:1517-1519.
13. Schiller, M., N. Blank, P. Heyder, M. Herrmann, U. S. Gaipl, J. R. Kalden, and H. M. Lorenz. 2005. Induction of apoptosis by spermine-metabolites in primary human blood cells and various tumor cell lines. *Apoptosis* 10:1151-1162.
14. Voll, R. E., and J. R. Kalden. 2005. Do We Need New Treatment That Goes beyond Tumor Necrosis Factor Blockers for Rheumatoid Arthritis? *Ann N Y Acad Sci* 1051:799-810.
15. Blank, N., R. Repp, W. Romer, J. R. Kalden, G. Helm, T. Harrer, H. M. Lorenz, and R. Janka. 2005. Multiple bone lesions of systemic multifocal fibrosclerosis. *AJR Am J Roentgenol* 185:668-670.
16. Kalden, J. R., C. Antoni, J. M. Alvaro-Gracia, B. Combe, P. Emery, J. M. Kremer, C. V. Strand, P. Van Riel, and J. S. Smolen. 2005. Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis. *J Rheumatol* 32:1620-1631.
17. Wellmann, U., M. Letz, M. Herrmann, S. Angermuller, J. R. Kalden, and T. H. Winkler. 2005. The evolution of human anti-double-stranded DNA autoantibodies. *Proc Natl Acad Sci U S A* 102:9258-9263.
18. Munoz, L. E., U. S. Gaipl, S. Franz, A. Sheriff, R. E. Voll, J. R. Kalden, and M. Herrmann. 2005. SLE--a disease of clearance deficiency? *Rheumatology (Oxford)* 44:1101-1107.
19. Gaipl, U. S., R. E. Voll, A. Sheriff, S. Franz, J. R. Kalden, and M. Herrmann. 2005. Impaired clearance of dying cells in systemic lupus erythematosus. *Autoimmun Rev* 4:189-194.
20. Harrer, E., M. Bauerle, B. Ferstl, P. Chaplin, B. Petzold, L. Mateo, A. Handley, M. Tzatzaris, J. Vollmar, S. Bergmann, M. Rittmaier, K. Eismann, S. Muller, J. R. Kalden, B. Spriewald, D. Willbold, and T. Harrer. 2005. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption. *Antivir Ther* 10:285-300.
21. Burkhardt, H., B. Sehnert, R. Bockermann, A. Engstrom, J. R. Kalden, and R. Holmdahl. 2005. Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis. *Eur J Immunol* 35:1643-1652.
22. Antoni, C. E., A. Kavanaugh, B. Kirkham, Z. Tutuncu, G. R. Burmester, U. Schneider, D. E. Furst, J. Molitor, E. Keystone, D. Gladman, B. Manger, S. Wassenberg, R. Weier, D. J. Wallace, M. H. Weisman, J. R. Kalden, and J. Smolen. 2005. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). *Arthritis Rheum* 52:1227-1236.
23. Smolen, J. S., C. Han, M. Bala, R. N. Maini, J. R. Kalden, D. van der Heijde, F. C. Breedveld, D. E. Furst, and P. E. Lipsky. 2005. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. *Arthritis Rheum* 52:1020-1030.
24. Strand, V., D. L. Scott, P. Emery, J. R. Kalden, J. S. Smolen, G. W. Cannon, P. Tugwell, and B. Crawford. 2005. Physical function and health related quality of life: analysis of 2-year data from

randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. *J Rheumatol* 32:590-601.

25. Kolowos, W., U. S. Gaipl, A. Sheriff, R. E. Voll, P. Heyder, P. Kern, J. R. Kalden, and M. Herrmann. 2005. Microparticles shed from different antigen-presenting cells display an individual pattern of surface molecules and a distinct potential of allogeneic T-cell activation. *Scand J Immunol* 61:226-233.
26. Distler, J. H., A. Jungel, O. Kowal-Bielecka, B. A. Michel, R. E. Gay, H. Sprott, M. Matucci-Cerinic, M. Chilla, K. Reich, J. R. Kalden, U. Muller-Ladner, H. M. Lorenz, S. Gay, and O. Distler. 2005. Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. *Arthritis Rheum* 52:856-864.
27. Kalden, J. R. 2005. Book Review. *Rheumatology (Oxford)*.
28. Spriewald, B. M., O. Witzke, R. Wassmuth, R. R. Wenzel, M. L. Arnold, T. Philipp, and J. R. Kalden. 2005. Distinct tumour necrosis factor alpha, interferon gamma, interleukin 10, and cytotoxic T cell antigen 4 gene polymorphisms in disease occurrence and end stage renal disease in Wegener's granulomatosis. *Ann Rheum Dis* 64:457-461.
29. Mueller, R. B., A. Skapenko, M. Grunke, J. Wendler, B. Stuhlmuller, J. R. Kalden, and H. Schulze-Koops. 2005. Regulation of myeloid cell function and major histocompatibility complex class II expression by tumor necrosis factor. *Arthritis Rheum* 52:451-460.
30. Kriegel, M. A., J. R. Kalden, and H. M. Lorenz. 2005. Lambert-Eaton myasthenic syndrome and undifferentiated connective tissue disease in a patient carrying the 8.1 ancestral haplotype. *Ann Rheum Dis* 64:167-168.
31. Distler, J. H., J. R. Kalden, S. Gray, and O. Distler. 2004. [Vascular changes in the pathogenesis of systemic sclerosis]. *Z Rheumatol* 63:446-450.
32. Arnold, M. L., T. Zacher, M. Dechant, J. R. Kalden, Doxiadis, II, and B. M. Spriewald. 2004. Detection and specification of noncomplement binding anti-HLA alloantibodies. *Hum Immunol* 65:1288-1296.
33. Appelt, U., A. Sheriff, U. S. Gaipl, J. R. Kalden, R. E. Voll, and M. Herrmann. 2005. Viable, apoptotic and necrotic monocytes expose phosphatidylserine: cooperative binding of the ligand Annexin V to dying but not viable cells and implications for PS-dependent clearance. *Cell Death Differ* 12:194-196.
34. St Clair, E. W., D. M. van der Heijde, J. S. Smolen, R. N. Maini, J. M. Bathon, P. Emery, E. Keystone, M. Schiff, J. R. Kalden, B. Wang, K. Dewoody, R. Weiss, and D. Baker. 2004. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. *Arthritis Rheum* 50:3432-3443.
35. Gaipl, U. S., S. Franz, R. E. Voll, A. Sheriff, J. R. Kalden, and M. Herrmann. 2004. Defects in the disposal of dying cells lead to autoimmunity. *Curr Rheumatol Rep* 6:401-407.
36. Sheriff, A., U. S. Gaipl, S. Franz, P. Heyder, R. E. Voll, J. R. Kalden, and M. Herrmann. 2004. Loss of GM1 surface expression precedes annexin V-phycoerythrin binding of neutrophils undergoing spontaneous apoptosis during in vitro aging. *Cytometry A* 62:75-80.
37. Bondanza, A., V. S. Zimmermann, P. Rovere-Querini, J. Turnay, I. E. Dumitriu, C. M. Stach, R. E. Voll, U. S. Gaipl, W. Bertling, E. Poschl, J. R. Kalden, A. A. Manfredi, and M. Herrmann. 2004.

Inhibition of phosphatidylserine recognition heightens the immunogenicity of irradiated lymphoma cells in vivo. *J Exp Med* 200:1157-1165.

38. Furst, D. E., F. C. Breedveld, J. R. Kalden, J. S. Smolen, G. R. Burmester, J. W. Bijlsma, M. Dougados, P. Emery, E. C. Keystone, L. Klareskog, and P. J. Mease. 2004. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. *Ann Rheum Dis* 63 Suppl 2:ii2-ii12.
39. Calin, A., B. A. Dijkmans, P. Emery, M. Hakala, J. Kalden, M. Leirisalo-Repo, E. M. Mola, C. Salvarani, R. Sanmarti, J. Sany, J. Sibilia, J. Sieper, S. van der Linden, E. Veys, A. M. Appel, and S. Fatenejad. 2004. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. *Ann Rheum Dis* 63:1594-1600.
40. Kalden, J. 2004. Apoptosis in systemic autoimmunity. *Autoimmun Rev* 3 Suppl 1:S9-10.
41. Dougados, M., N. Betteridge, G. R. Burmester, L. Euller-Ziegler, F. Guillemin, J. Hirvonen, J. Lloyd, S. Ozen, J. A. Da Silva, P. Emery, J. R. Kalden, T. Kvien, M. Matucci-Cerinic, and J. Smolen. 2004. EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. *Ann Rheum Dis* 63:1172-1176.
42. Gabler, C., N. Blank, T. Hieronymus, M. Schiller, J. H. Berden, J. R. Kalden, and H. M. Lorenz. 2004. Extranuclear detection of histones and nucleosomes in activated human lymphoblasts as an early event in apoptosis. *Ann Rheum Dis* 63:1135-1144.
43. Sheriff, A., U. S. Gaipl, R. E. Voll, J. R. Kalden, and M. Herrmann. 2004. Apoptosis and systemic lupus erythematosus. *Rheum Dis Clin North Am* 30:505-527, viii-ix.
44. Lorenz, H. M., and J. R. Kalden. 2004. Dysregulation of apoptosis as mechanism supporting the induction of autoimmunity. *Curr Rheumatol Rep* 6:249-251.
45. Sehnert, B., A. Cavcic, B. Bohm, J. R. Kalden, K. S. Nandakumar, R. Holmdahl, and H. Burkhardt. 2004. Antileukoproteinase: modulation of neutrophil function and therapeutic effects on anti-type II collagen antibody-induced arthritis. *Arthritis Rheum* 50:2347-2359.
46. Dechant, C., P. Schauenberg, C. E. Antoni, H. G. Kraetsch, J. R. Kalden, and B. Manger. 2004. [Longterm outcome of TNF blockade in adult-onset Still's disease]. *Dtsch Med Wochenschr* 129:1308-1312.
47. Kalden, J. R., J. S. Smolen, P. Emery, P. L. van Riel, M. Dougados, C. V. Strand, and F. C. Breedveld. 2004. Lefunomide in combination therapy. *J Rheumatol Suppl* 71:25-30.
48. van Riel, P. L., J. S. Smolen, P. Emery, J. R. Kalden, M. Dougados, C. V. Strand, and F. C. Breedveld. 2004. Leflunomide: a manageable safety profile. *J Rheumatol Suppl* 71:21-24.
49. Smolen, J. S., P. Emery, J. R. Kalden, P. L. Van Riel, M. Dougados, C. V. Strand, and F. C. Breedveld. 2004. The efficacy of leflunomide monotherapy in rheumatoid arthritis: towards the goals of disease modifying antirheumatic drug therapy. *J Rheumatol Suppl* 71:13-20.
50. Manger, K., C. Dechant, J. R. Kalden, and B. Manger. 2004. Clinical images: Periarticular inflammation in rapidly developing Jaccoud's arthropathy. *Arthritis Rheum* 50:1700.

51. van der Heijde, D., J. Kalden, D. Scott, J. Smolen, and V. Strand. 2004. Long term evaluation of radiographic disease progression in a subset of patients with rheumatoid arthritis treated with leflunomide beyond 2 years. *Ann Rheum Dis* 63:737-739.
52. Breedveld, F. C., and J. R. Kalden. 2004. Appropriate and effective management of rheumatoid arthritis. *Ann Rheum Dis* 63:627-633.
53. Skapenko, A., G. U. Niedobitek, J. R. Kalden, P. E. Lipsky, and H. Schulze-Koops. 2004. Generation and regulation of human Th1-biased immune responses in vivo: a critical role for IL-4 and IL-10. *J Immunol* 172:6427-6434.
54. Kriegel, M. A., T. Lohmann, C. Gabler, N. Blank, J. R. Kalden, and H. M. Lorenz. 2004. Defective suppressor function of human CD4+ CD25+ regulatory T cells in autoimmune polyglandular syndrome type II. *J Exp Med* 199:1285-1291.
55. Maini, R. N., F. C. Breedveld, J. R. Kalden, J. S. Smolen, D. Furst, M. H. Weisman, E. W. St Clair, G. F. Keenan, D. van der Heijde, P. A. Marsters, and P. E. Lipsky. 2004. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. *Arthritis Rheum* 50:1051-1065.
56. Gabler, C., N. Blank, S. Winkler, J. R. Kalden, and H. M. Lorenz. 2003. Accumulation of histones in cell lysates precedes expression of apoptosis-related phagocytosis signals in human lymphoblasts. *Ann N Y Acad Sci* 1010:221-224.
57. Klareskog, L., D. van der Heijde, J. P. de Jager, A. Gough, J. Kalden, M. Malaise, E. Martin Mola, K. Pavelka, J. Sany, L. Settas, J. Wajdula, R. Pedersen, S. Fatenejad, and M. Sanda. 2004. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. *Lancet* 363:675-681.
58. Gaipl, U. S., T. D. Beyer, P. Heyder, S. Kuenkele, A. Bottcher, R. E. Voll, J. R. Kalden, and M. Herrmann. 2004. Cooperation between C1q and DNase I in the clearance of necrotic cell-derived chromatin. *Arthritis Rheum* 50:640-649.
59. Skapenko, A., J. Leipe, U. Niesner, K. Devriendt, R. Beetz, A. Radbruch, J. R. Kalden, P. E. Lipsky, and H. Schulze-Koops. 2004. GATA-3 in human T cell helper type 2 development. *J Exp Med* 199:423-428.
60. Distler, J. H., C. Hagen, A. Hirth, U. Muller-Ladner, H. M. Lorenz, A. del Rosso, B. A. Michel, R. E. Gay, R. Nanagara, K. Nishioka, M. Matucci-Cerinic, J. R. Kalden, S. Gay, and O. Distler. 2004. Bucillamine induces the synthesis of vascular endothelial growth factor dose-dependently in systemic sclerosis fibroblasts via nuclear factor-kappaB and simian virus 40 promoter factor 1 pathways. *Mol Pharmacol* 65:389-399.
61. Breedveld, F. C., P. Emery, E. Keystone, K. Patel, D. E. Furst, J. R. Kalden, E. W. St Clair, M. Weisman, J. Smolen, P. E. Lipsky, and R. N. Maini. 2004. Infliximab in active early rheumatoid arthritis. *Ann Rheum Dis* 63:149-155.
62. Dumitriu, I. E., R. E. Voll, W. Kolowos, U. S. Gaipl, P. Heyder, J. R. Kalden, and M. Herrmann. 2004. UV irradiation inhibits ABC transporters via generation of ADP-ribose by concerted action of poly(ADP-ribose) polymerase-1 and glycohydrolase. *Cell Death Differ* 11:314-320.

63. Fritzler, M. J., A. Wiik, E. M. Tan, J. S. Smolen, J. S. McDougal, E. K. Chan, T. P. Gordon, J. A. Hardin, J. R. Kalden, R. G. Lahita, R. N. Maini, W. H. Reeves, N. F. Rothfield, Y. Takasaki, M. Wilson, M. G. Byrd, L. Slivka, and J. A. Koziol. 2003. A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. III. Comparative performance characteristics of academic and manufacturers' laboratories. *J Rheumatol* 30:2374-2381.
64. Repp, R., H. H. van Ojik, T. Valerius, G. Groenewegen, G. Wieland, C. Oetzel, B. Stockmeyer, W. Becker, M. Eisenhut, H. Steininger, Y. M. Deo, G. H. Blijham, J. R. Kalden, J. G. van de Winkel, and M. Gramatzki. 2003. Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcγRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer. *Br J Cancer* 89:2234-2243.
65. Hagenhofer, M., H. Germaier, C. Hohenadl, P. Rohwer, J. R. Kalden, and M. Herrmann. 1998. UV-B irradiated cell lines execute programmed cell death in various forms. *Apoptosis* 3:123-132.
66. van de Putte, L. B., R. Rau, F. C. Breedveld, J. R. Kalden, M. G. Malaise, P. L. van Riel, M. Schattenkirchner, P. Emery, G. R. Burmester, H. Zeidler, H. M. Moutsopoulos, K. Beck, and H. Kupper. 2003. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. *Ann Rheum Dis* 62:1168-1177.
67. Stockmeyer, B., T. Beyer, W. Neuhuber, R. Repp, J. R. Kalden, T. Valerius, and M. Herrmann. 2003. Polymorphonuclear granulocytes induce antibody-dependent apoptosis in human breast cancer cells. *J Immunol* 171:5124-5129.
68. Gabler, C., J. R. Kalden, and H. M. Lorenz. 2003. The putative role of apoptosis-modified histones for the induction of autoimmunity in Systemic Lupus Erythematosus. *Biochem Pharmacol* 66:1441-1446.
69. Furst, D. E., F. C. Breedveld, J. R. Kalden, J. S. Smolen, G. R. Burmester, M. Dougados, P. Emery, A. Gibofsky, A. F. Kavanaugh, E. C. Keystone, L. Klareskog, A. S. Russell, L. B. van de Putte, and M. H. Weisman. 2003. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003). *Ann Rheum Dis* 62 Suppl 2:ii2-9.
70. Dumitriu, I. E., F. Roedel, T. D. Beyer, U. S. Gaipl, J. R. Kalden, and M. Herrmann. 2003. UV or X-irradiation increases the cytoplasmic accumulation of rhodamine 123 in various cancer cell lines. *Strahlenther Onkol* 179:564-570.
71. Heyder, P., U. S. Gaipl, T. D. Beyer, R. E. Voll, P. M. Kern, C. Stach, J. R. Kalden, and M. Herrmann. 2003. Early detection of apoptosis by staining of acid-treated apoptotic cells with FITC-labeled lectin from *Narcissus pseudonarcissus*. *Cytometry A* 55:86-93.
72. Schulze-Koops, H., H. Burkhardt, and J. R. Kalden. 1999. What we have learned from trials of immunomodulatory agents in rheumatoid arthritis: Future directions. *Drugs Today (Barc)* 35:327-351.
73. Manger, K., M. Kusus, C. Forster, D. Ropers, W. G. Daniel, J. R. Kalden, S. Achenbach, and B. Manger. 2003. Factors associated with coronary artery calcification in young female patients with SLE. *Ann Rheum Dis* 62:846-850.
74. Kriegel, M. A., U. Huffmeier, E. Scherb, C. Scheidig, T. Geiler, J. R. Kalden, A. Reis, and H. M. Lorenz. 2003. Tumor necrosis factor receptor-associated periodic syndrome characterized by a

mutation affecting the cleavage site of the receptor: implications for pathogenesis. *Arthritis Rheum* 48:2386-2388.

75. Kalden, J. R. 2003. Introduction. *Rheumatology (Oxford)* 42 Suppl 2:II1-II2.
76. Kalden, J. R., M. Schattenkirchner, H. Sorensen, P. Emery, C. Deighton, B. Rozman, and F. Breedveld. 2003. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study. *Arthritis Rheum* 48:1513-1520.
77. Straub, R. H., G. Pongratz, J. Scholmerich, F. Kees, T. F. Schaible, C. Antoni, J. R. Kalden, and H. M. Lorenz. 2003. Long-term anti-tumor necrosis factor antibody therapy in rheumatoid arthritis patients sensitizes the pituitary gland and favors adrenal androgen secretion. *Arthritis Rheum* 48:1504-1512.
78. Kuenkele, S., T. D. Beyer, R. E. Voll, J. R. Kalden, and M. Herrmann. 2003. Impaired clearance of apoptotic cells in systemic lupus erythematosus: challenge of T and B cell tolerance. *Curr Rheumatol Rep* 5:175-177.
79. Wagner, U., S. Kaltenhauser, M. Pierer, W. Seidel, M. Troltsch, H. Hantzschel, J. R. Kalden, and R. Wassmuth. 2003. Prospective analysis of the impact of HLA-DR and -DQ on joint destruction in recent-onset rheumatoid arthritis. *Rheumatology (Oxford)* 42:553-562.
80. Gaipf, U. S., T. D. Beyer, I. Baumann, R. E. Voll, C. M. Stach, P. Heyder, J. R. Kalden, A. Manfredi, and M. Herrmann. 2003. Exposure of anionic phospholipids serves as anti-inflammatory and immunosuppressive signal--implications for antiphospholipid syndrome and systemic lupus erythematosus. *Immunobiology* 207:73-81.
81. Smolen, J. S., F. C. Breedveld, M. H. Schiff, J. R. Kalden, P. Emery, G. Eberl, P. L. van Riel, and P. Tugwell. 2003. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. *Rheumatology (Oxford)* 42:244-257.
82. Birck, R., K. Warnatz, H. M. Lorenz, M. Choi, M. Haubitz, M. Grunke, H. H. Peter, J. R. Kalden, U. Gobel, J. M. Drexler, O. Hotta, R. Nowack, and F. J. Van Der Woude. 2003. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. *J Am Soc Nephrol* 14:440-447.
83. Gaipf, U. S., J. Brunner, T. D. Beyer, R. E. Voll, J. R. Kalden, and M. Herrmann. 2003. Disposal of dying cells: a balancing act between infection and autoimmunity. *Arthritis Rheum* 48:6-11.
84. Zacher, T., I. Knerr, W. Rascher, J. R. Kalden, and R. Wassmuth. 2002. Characterization of monocyte-derived dendritic cells in recent-onset diabetes mellitus type 1. *Clin Immunol* 105:17-24.
85. Matzkies, F. G., B. Manger, M. Schmitt-Haendle, T. Nagel, H. G. Kraetsch, J. R. Kalden, and H. Schulze-Koops. 2003. Severe septicaemia in a patient with polychondritis and Sweet's syndrome after initiation of treatment with infliximab. *Ann Rheum Dis* 62:81-82.
86. Blank, N., C. Gabler, M. Schiller, M. Kriegel, J. R. Kalden, and H. M. Lorenz. 2002. A fast, simple and sensitive method for the detection and quantification of detergent-resistant membranes. *J Immunol Methods* 271:25-35.
87. Kalden, J. R. 2002. Expanding role of biologic agents in rheumatoid arthritis. *J Rheumatol Suppl* 66:27-37.

88. Manger, K., B. Manger, R. Repp, M. Geisselbrecht, A. Geiger, A. Pfahlberg, T. Harrer, and J. R. Kalden. 2002. Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. *Ann Rheum Dis* 61:1065-1070.
89. Kalden, J. R., H. Lochs, and H. Wollheim. 2002. [Remicade in therapy of rheumatoid arthritis and Crohn diseases--no reason for panic]. *Z Rheumatol* 61:466-468.
90. Antoni, C., C. Dechant, P. D. Hanns-Martin Lorenz, J. Wendler, A. Ogilvie, M. Lueftl, D. Kalden-Nemeth, J. R. Kalden, and B. Manger. 2002. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. *Arthritis Rheum* 47:506-512.
91. Furst, D. E., F. C. Breedveld, J. R. Kalden, J. S. Smolen, C. E. Antoni, J. W. Bijlsma, G. R. Burmester, B. Cronstein, E. C. Keystone, A. Kavanaugh, and L. Klareskog. 2002. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002). *Ann Rheum Dis* 61 Suppl 2:ii2-7.
92. Choy, E. H., G. S. Panayi, P. Emery, S. Madden, F. C. Breedveld, M. C. Kraan, J. R. Kalden, A. Rascu, J. C. Brown, N. Rapson, and J. M. Johnston. 2002. Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial. *Rheumatology (Oxford)* 41:1142-1148.
93. Burkhardt, H., T. Koller, A. Engstrom, K. S. Nandakumar, J. Turnay, H. G. Kraetsch, J. R. Kalden, and R. Holmdahl. 2002. Epitope-specific recognition of type II collagen by rheumatoid arthritis antibodies is shared with recognition by antibodies that are arthritogenic in collagen-induced arthritis in the mouse. *Arthritis Rheum* 46:2339-2348.
94. Dimitrova, P., A. Skapenko, M. L. Herrmann, R. Schleyerbach, J. R. Kalden, and H. Schulze-Koops. 2002. Restriction of de novo pyrimidine biosynthesis inhibits Th1 cell activation and promotes Th2 cell differentiation. *J Immunol* 169:3392-3399.
95. Blank, N., R. Burger, B. Duerr, F. Bakker, A. Wohlfarth, I. Dumitriu, J. R. Kalden, and M. Herrmann. 2002. MEK inhibitor U0126 interferes with immunofluorescence analysis of apoptotic cell death. *Cytometry* 48:179-184.
96. Stockmeyer, B., M. Schiller, R. Repp, H. M. Lorenz, J. R. Kalden, M. Gramatzki, and T. Valerius. 2002. Enhanced killing of B lymphoma cells by granulocyte colony-stimulating factor-primed effector cells and Hu1D10--a humanized human leucocyte antigen DR antibody. *Br J Haematol* 118:959-967.
97. Beyer, T. D., W. Kolowos, I. E. Dumitriu, R. E. Voll, P. Heyder, U. S. Gaipl, J. R. Kalden, and M. Herrmann. 2002. Apoptosis of the teratocarcinoma cell line Tera-1 leads to the cleavage of HERV-K10gag proteins by caspases and/or granzyme B. *Scand J Immunol* 56:303-309.
98. Manger, K., R. Repp, M. Jansen, M. Geisselbrecht, R. Wassmuth, N. A. Westerdaal, A. Pfahlberg, B. Manger, J. R. Kalden, and J. G. van de Winkel. 2002. Fcγ receptor IIa, IIIa, and IIIb polymorphisms in German patients with systemic lupus erythematosus: association with clinical symptoms. *Ann Rheum Dis* 61:786-792.
99. Simon, L. S., J. S. Smolen, S. B. Abramson, G. Appel, C. Bombardier, D. C. Brater, F. C. Breedveld, K. Brune, G. R. Burmester, L. J. Crofford, M. Dougados, R. N. DuBois, G. A. Fitzgerald, W. Frishman, L. A. Garcia Rodriguez, M. C. Hochberg, J. R. Kalden, L. Laine, M. J.

- Langman, S. M. Prescott, L. B. van de Putte, A. Whelton, W. B. White, and G. H. Willaims. 2002. Controversies in COX-2 selective inhibition. *J Rheumatol* 29:1501-1510.
100. Kalden, J. R. 2002. Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases. *Arthritis Res* 4 Suppl 2:S34-40.
101. Lorenz, H. M., and J. R. Kalden. 2002. Perspectives for TNF-alpha-targeting therapies. *Arthritis Res* 4 Suppl 3:S17-24.
102. Shoenfeld, Y., Y. Sherer, and J. R. Kalden. 2002. The expanding world of autoimmunity. *Trends Immunol* 23:278-279.
103. Lorenz, H. M., M. Grunke, T. Hieronymus, S. Winkler, N. Blank, A. Rascu, J. Wendler, T. Geiler, and J. R. Kalden. 2002. Hyporesponsiveness to gammac-chain cytokines in activated lymphocytes from patients with systemic lupus erythematosus leads to accelerated apoptosis. *Eur J Immunol* 32:1253-1263.
104. Tzioufas, A. G., R. Wassmuth, U. G. Dafni, A. Guialis, H. J. Haga, D. A. Isenberg, R. Jonsson, J. R. Kalden, H. Kiener, C. Sakarellos, J. S. Smolen, N. Sutcliffe, C. Vitali, E. Yiannaki, and H. M. Moutsopoulos. 2002. Clinical, immunological, and immunogenetic aspects of autoantibody production against Ro/SSA, La/SSB and their linear epitopes in primary Sjogren's syndrome (pSS): a European multicentre study. *Ann Rheum Dis* 61:398-404.
105. Kraetsch, H. G., C. Antoni, J. R. Kalden, and B. Manger. 2001. Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences. *Ann Rheum Dis* 60 Suppl 3:iii55-57.
106. Furst, D. E., E. C. Keystone, F. C. Breedveld, J. R. Kalden, J. S. Smolen, C. E. Antoni, G. R. Burmester, L. J. Crofford, and A. Kavanaugh. 2001. Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001). *Ann Rheum Dis* 60 Suppl 3:iii2-5.
107. Emery, P., F. C. Breedveld, M. Dougados, J. R. Kalden, M. H. Schiff, and J. S. Smolen. 2002. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. *Ann Rheum Dis* 61:290-297.
108. Rautenstrauch, J., H. Burkhardt, H. Schulze-Koops, R. Wassmuth, T. Harrer, B. Spriewald, B. Manger, and J. R. Kalden. 2001. [Presentation of the Erlangen Competence Center]. *Z Rheumatol* 60:496-505.
109. Tan, E. M., J. S. Smolen, J. S. McDougal, M. J. Fritzler, T. Gordon, J. A. Hardin, J. R. Kalden, R. G. Lahita, R. N. Maini, W. H. Reeves, N. F. Rothfield, Y. Takasaki, A. Wiik, M. Wilson, and J. A. Koziol. 2002. A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. II. Potential for quantitation of antibody content. *J Rheumatol* 29:68-74.
110. Baumann, I., W. Kolowos, R. E. Voll, B. Manger, U. Gaipl, W. L. Neuhuber, T. Kirchner, J. R. Kalden, and M. Herrmann. 2002. Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. *Arthritis Rheum* 46:191-201.
111. Schulze-Koops, H., and J. R. Kalden. 2001. The balance of Th1/Th2 cytokines in rheumatoid arthritis. *Best Pract Res Clin Rheumatol* 15:677-691.

112. Stadick, H., B. Stockmeyer, R. Kuhn, K. M. Schrott, J. R. Kalden, M. J. Glennie, J. G. van de Winkel, M. Gramatzki, T. Valerius, and D. Elsasser. 2002. Epidermal growth factor receptor and g250: useful target antigens for antibody mediated cellular cytotoxicity against renal cell carcinoma? *J Urol* 167:707-712.
113. Lorenz, H. M., and J. R. Kalden. 2001. [New therapy developments in rheumatoid arthritis]. *Z Rheumatol* 60:326-332.
114. Dumitriu, I. E., W. Mohr, W. Kolowos, P. Kern, J. R. Kalden, and M. Herrmann. 2001. 5,6-carboxyfluorescein diacetate succinimidyl ester-labeled apoptotic and necrotic as well as detergent-treated cells can be traced in composite cell samples. *Anal Biochem* 299:247-252.
115. Skapenko, A., J. R. Kalden, and H. Schulze-Koops. 2001. Treatment of rheumatoid arthritis in the third millennium. *Scand J Rheumatol* 30:249-254.
116. Lorenz, H. M., M. Herrmann, and J. R. Kalden. 2001. The pathogenesis of autoimmune diseases. *Scand J Clin Lab Invest Suppl* 235:16-26.
117. Bohm, B. B., T. Aigner, C. P. Blobel, J. R. Kalden, and H. Burkhardt. 2001. Highly enhanced expression of the disintegrin metalloproteinase MDC15 (metargidin) in rheumatoid synovial tissue. *Arthritis Rheum* 44:2046-2054.
118. Scott, D. L., J. S. Smolen, J. R. Kalden, L. B. van de Putte, A. Larsen, T. K. Kvien, M. Schattenkirchner, P. Nash, C. Oed, and I. Loew-Friedrich. 2001. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. *Ann Rheum Dis* 60:913-923.
119. Kalden, J. R., D. L. Scott, J. S. Smolen, M. Schattenkirchner, B. Rozman, B. D. Williams, T. K. Kvien, P. Jones, R. B. Williams, C. Oed, and R. Rosenberg. 2001. Improved functional ability in patients with rheumatoid arthritis--longterm treatment with leflunomide versus sulfasalazine. European Leflunomide Study Group. *J Rheumatol* 28:1983-1991.
120. Gaipf, U. S., S. Kuenkele, R. E. Voll, T. D. Beyer, W. Kolowos, P. Heyder, J. R. Kalden, and M. Herrmann. 2001. Complement binding is an early feature of necrotic and a rather late event during apoptotic cell death. *Cell Death Differ* 8:327-334.
121. Kern, P. M., L. Keilholz, J. R. Kalden, and M. Herrmann. 2001. Apoptotic UV-irradiated lymphocytes undergo protease mediated shedding of L-selectin in vitro. *Transfus Apher Sci* 24:99-101.
122. Burkhardt, H., J. R. Kalden, and H. Schulze-Koops. 2001. Chicken and egg in autoimmunity and joint inflammation. *Trends Immunol* 22:291-293.
123. Kalden, J. R. 2001. How do the biologics fit into the current DMARD armamentarium? *J Rheumatol Suppl* 62:27-35.
124. Kolowos, W., U. S. Gaipf, R. E. Voll, C. Frank, J. P. Haas, T. D. Beyer, J. R. Kalden, and M. Herrmann. 2001. CD4 positive peripheral T cells from patients with systemic lupus erythematosus (SLE) are clonally expanded. *Lupus* 10:321-331.
125. Wassmuth, R., I. A. Hauser, K. Schuler, H. Erxleben, M. L. Arnold, C. A. Koelman, F. H. Claas, and J. R. Kalden. 2001. Differential inhibitory effects of intravenous immunoglobulin preparations on HLA-alloantibodies in vitro. *Transplantation* 71:1436-1442.

126. Wendler, J., T. Hummel, M. Reissinger, B. Manger, E. Pauli, J. R. Kalden, and G. Kobal. 2001. Patients with rheumatoid arthritis adapt differently to repetitive painful stimuli compared to healthy controls. *J Clin Neurosci* 8:272-277.
127. Kraetsch, H. G., C. Unger, P. Wernhoff, C. Schneider, J. R. Kalden, R. Holmdahl, and H. Burkhardt. 2001. Cartilage-specific autoimmunity in rheumatoid arthritis: characterization of a triple helical B cell epitope in the integrin-binding-domain of collagen type II. *Eur J Immunol* 31:1666-1673.
128. Kalden, J. R. 2000. The application of infliximab (Remicade), a chimeric monoclonal antibody, in the treatment of rheumatic diseases. *Isr Med Assoc J* 2 Suppl:11-12.
129. Blank, N., M. Kriegel, T. Hieronymus, T. Geiler, S. Winkler, J. R. Kalden, and H. M. Lorenz. 2001. CD45 tyrosine phosphatase controls common gamma-chain cytokine-mediated STAT and extracellular signal-related kinase phosphorylation in activated human lymphoblasts: inhibition of proliferation without induction of apoptosis. *J Immunol* 166:6034-6040.
130. Stach, C. M., X. Turnay, R. E. Voll, P. M. Kern, W. Kolowos, T. D. Beyer, J. R. Kalden, and M. Herrmann. 2000. Treatment with annexin V increases immunogenicity of apoptotic human T-cells in Balb/c mice. *Cell Death Differ* 7:911-915.
131. Lorenz, H. M., and J. R. Kalden. 2001. [Cytokines and anti-cytokine therapy in rheumatoid arthritis]. *Internist (Berl)* 42:55-56, 59-63.
132. Ogilvie, A. L., C. Antoni, C. Dechant, B. Manger, J. R. Kalden, G. Schuler, and M. Luftl. 2001. Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. *Br J Dermatol* 144:587-589.
133. Lorenz, H. M., M. Herrmann, T. Winkler, U. Gaipl, and J. R. Kalden. 2000. Role of apoptosis in autoimmunity. *Apoptosis* 5:443-449.
134. Skapenko, A., P. E. Lipsky, H. G. Kraetsch, J. R. Kalden, and H. Schulze-Koops. 2001. Antigen-independent Th2 cell differentiation by stimulation of CD28: regulation via IL-4 gene expression and mitogen-activated protein kinase activation. *J Immunol* 166:4283-4292.
135. Gause, A., B. Manger, J. R. Kalden, and G. R. Burmester. 2001. [Therapy of inflammatory rheumatic diseases: from current practice standards to future]. *Internist (Berl)* 42:223-232, 234-226.
136. Swaak, A. J., H. G. van den Brink, R. J. Smeenk, K. Manger, J. R. Kalden, S. Tosi, Z. Domljan, B. Rozman, D. Logar, G. Pokorny, L. Kovacs, A. Kovacs, P. G. Vlachoyiannopoulos, H. M. Moutsopoulos, H. Chwalinska-Sadowska, E. Kiss, N. Cikes, B. Anic, M. Schneider, R. Fischer, S. Bombardieri, M. Mosca, W. Graninger, and J. S. Smolen. 2001. Systemic lupus erythematosus. Disease outcome in patients with a disease duration of at least 10 years: second evaluation. *Lupus* 10:51-58.
137. Zhang, W., T. Winkler, J. R. Kalden, and M. Reichlin. 2001. Isolation of human anti-idiotypes broadly cross reactive with anti-dsDNA antibodies from patients with Systemic lupus erythematosus. *Scand J Immunol* 53:192-197.
138. Swaak, A. J., H. van de Brink, R. J. Smeenk, K. Manger, J. R. Kalden, S. Tosi, A. Marchesoni, Z. Domljan, B. Rozman, D. Logar, G. Pokorny, L. Kovacs, A. Kovacs, P. G. Vlachoyiannopoulos, H. M. Moutsopoulos, H. Chwalinska-Sadowska, B. Dratwianka, E. Kiss, N. Cikes, B. Anic, M. Schneider, R. Fischer, S. Bombardieri, M. Mosca, W. Graninger, and J. S. Smolen. 2001.

Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT). *Rheumatology (Oxford)* 40:89-94.

139. Brouwer, R., G. J. Hengstman, W. Vree Egberts, H. Ehrfeld, B. Bozic, A. Ghirardello, G. Grondal, M. Hietarinta, D. Isenberg, J. R. Kalden, I. Lundberg, H. Moutsopoulos, P. Roux-Lombard, J. Vencovsky, A. Wikman, H. P. Seelig, B. G. van Engelen, and W. J. van Venrooij. 2001. Autoantibody profiles in the sera of European patients with myositis. *Ann Rheum Dis* 60:116-123.
140. Huss, R., C. Haas, M. Herrmann, J. R. Kalden, and U. Lohrs. 2000. Impairment of genomic DNA binding to a putative dysfunctional receptor on erythrocytes independent of complement and antibodies in systemic lupus erythematosus. *Virchows Arch* 437:380-387.
141. Lipsky, P. E., D. M. van der Heijde, E. W. St Clair, D. E. Furst, F. C. Breedveld, J. R. Kalden, J. S. Smolen, M. Weisman, P. Emery, M. Feldmann, G. R. Harriman, and R. N. Maini. 2000. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. *N Engl J Med* 343:1594-1602.
142. Schulze-Koops, H., and J. R. Kalden. 2000. Where is biological therapy going? *Arthritis Res* 2:337-341.
143. Witte, T., T. Matthias, F. C. Arnett, H. H. Peter, K. Hartung, C. Sachse, R. Wigand, A. Braner, J. R. Kalden, H. J. Lakomek, and R. E. Schmidt. 2000. IgA and IgG autoantibodies against alpha-fodrin as markers for Sjogren's syndrome. Systemic lupus erythematosus. *J Rheumatol* 27:2617-2620.
144. Hundt, M., K. Manger, T. Dorner, B. Grimbacher, P. Kalden, A. Rascu, D. Weber, G. R. Burmester, H. H. Peter, J. R. Kalden, and R. E. Schmidt. 2000. Treatment of acute exacerbation of systemic lupus erythematosus with high-dose intravenous immunoglobulin. *Rheumatology (Oxford)* 39:1301-1302.
145. Stockmeyer, B., M. Dechant, M. van Egmond, A. L. Tutt, K. Sundarapandiyam, R. F. Graziano, R. Repp, J. R. Kalden, M. Gramatzki, M. J. Glennie, J. G. van de Winkel, and T. Valerius. 2000. Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy. *J Immunol* 165:5954-5961.
146. Furst, D. E., F. C. Breedveld, G. R. Burmester, J. J. Crofford, P. Emery, M. Feldmann, J. R. Kalden, A. F. Kavanaugh, E. C. Keystone, L. G. Klareskog, P. E. Lipsky, R. N. Maini, A. S. Russell, D. L. Scott, J. S. Smolen, L. B. Van de Putte, T. L. Visher, and M. H. Weisman. 2000. Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000). *Ann Rheum Dis* 59 Suppl 1:i1-2.
147. Editors, G., F. C. Breedveld, J. R. Kalden, and J. S. Smolen. 2000. Advances in targeted therapies II. *Ann Rheum Dis* 59 Suppl 1:I.
148. Herrmann, M., T. Winkler, U. Gaipl, H. Lorenz, T. Geiler, and J. R. Kalden. 2000. Etiopathogenesis of systemic lupus erythematosus. *Int Arch Allergy Immunol* 123:28-35.
149. Hieronymus, T., P. Grotsch, N. Blank, M. Grunke, D. Capraru, T. Geiler, S. Winkler, J. R. Kalden, and H. M. Lorenz. 2000. Chlorpromazine induces apoptosis in activated human lymphoblasts: a mechanism supporting the induction of drug-induced lupus erythematosus? *Arthritis Rheum* 43:1994-2004.

150. Kern, P. M., L. Keilholz, C. Forster, C. Stach, T. D. Beyer, U. S. Gaipl, J. R. Kalden, R. Hallmann, and M. Herrmann. 2000. UVB-irradiated T-cells undergoing apoptosis lose L-selectin by metalloprotease-mediated shedding. *Int J Radiat Biol* 76:1265-1271.
151. Kasten, S., A. Goldwisch, M. Schmitt, A. Rascu, M. Grunke, C. Dechant, J. R. Kalden, and T. Harrer. 2000. Positive influence of the Delta32CCR5 allele on response to highly active antiretroviral therapy (HAART) in HIV-1 infected patients. *Eur J Med Res* 5:323-328.
152. Boorboor, P., B. E. Drescher, K. Hartung, C. Sachse, B. P. Tsao, P. M. Schneider, J. R. Kalden, H. J. Lakomek, H. H. Peter, R. E. Schmidt, and T. Witte. 2000. Poly(ADP-ribose) polymerase polymorphisms are not a genetic risk factor for systemic lupus erythematosus in German Caucasians. *J Rheumatol* 27:2061.
153. Herrmann, M., R. E. Voll, and J. R. Kalden. 2000. Etiopathogenesis of systemic lupus erythematosus. *Immunol Today* 21:424-426.
154. Keitel, W., E. Genth, E. Gromnica-Ihle, H. Hantzschel, J. R. Kalden, H. Mathies, H. H. Raspe, M. Schneider, H. Warnatz, J. Zacher, and H. H. Abholz. 2000. [Guideline for the joint swelling symptom--primary physician problem management and referral indications. German Society of Rheumatology "Quality Assurance" Committee]. *Z Rheumatol* 59:151-161.
155. Kern, P. M., M. Herrmann, B. Stockmeyer, J. R. Kalden, T. Valerius, and R. Repp. 2000. Flow cytometric discrimination between viable neutrophils, apoptotic neutrophils and eosinophils by double labelling of permeabilized blood granulocytes. *J Immunol Methods* 241:11-18.
156. Nagel, T., J. R. Kalden, and B. Manger. 2000. Co-stimulation of IL-2 production by CD28 is independent of tyrosine-based signaling motifs in a murine T cell hybridoma. *Eur J Immunol* 30:1632-1637.
157. Smolen, J. S., F. C. Breedveld, G. R. Burmester, B. Combe, P. Emery, J. R. Kalden, L. Klareskog, R. N. Maini, R. Numo, L. B. van De Putte, P. L. van Riel, and V. Rodriguez-Valverde. 2000. Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis. *Ann Rheum Dis* 59:504-505.
158. Hieronymus, T., N. Blank, M. Gruenke, S. Winkler, J. P. Haas, J. R. Kalden, and H. M. Lorenz. 2000. CD 95-independent mechanisms of IL-2 deprivation-induced apoptosis in activated human lymphocytes. *Cell Death Differ* 7:538-547.
159. Schmitt, M., E. Harrer, A. Goldwisch, M. Bauerle, I. Graedner, J. R. Kalden, and T. Harrer. 2000. Specific recognition of lamivudine-resistant HIV-1 by cytotoxic T lymphocytes. *Aids* 14:653-658.
160. Witte, T., K. Hartung, C. Sachse, T. Matthias, M. Fricke, J. R. Kalden, H. J. Lakomek, H. H. Peter, and R. E. Schmidt. 2000. Rheumatoid factors in systemic lupus erythematosus: association with clinical and laboratory parameters. SLE study group. *Rheumatol Int* 19:107-111.
161. Kalden, J. R. 1999. Changing the course of rheumatoid arthritis. Introduction. *Scand J Rheumatol Suppl* 112:1.
162. Meyer, P., H. Burkhardt, E. Palombo-Kinne, W. Grunder, R. Brauer, K. J. Stiller, J. R. Kalden, W. Becker, and R. W. Kinne. 2000. 123I-antileukoproteinase scintigraphy reveals microscopic cartilage alterations in the contralateral knee joint of rats with "monarticular" antigen-induced arthritis. *Arthritis Rheum* 43:298-310.

163. Lorenz, H. M., M. Grunke, T. Hieronymus, C. Antoni, H. Nusslein, T. F. Schaible, B. Manger, and J. R. Kalden. 2000. In vivo blockade of tumor necrosis factor-alpha in patients with rheumatoid arthritis: longterm effects after repeated infusion of chimeric monoclonal antibody cA2. *J Rheumatol* 27:304-310.
164. Witte, T., K. Hartung, C. Sachse, M. Fricke, S. Buyny, H. Deicher, J. R. Kalden, H. J. Lakomek, H. H. Peter, and R. E. Schmidt. 1999. Thrombomodulin in systemic lupus erythematosus: association with clinical and laboratory parameters. *Rheumatol Int* 19:15-18.
165. Paulus, H. E., and J. R. Kalden. 1999. Workshop summary: the emerging role of biologicals in the treatment of patients with newly diagnosed rheumatoid arthritis. *Rheumatology (Oxford)* 38 Suppl 2:45-46.
166. Kern, P., J. R. Kalden, and B. Manger. 2000. Inflammatory arterial stenosis: followup with color Doppler sonography. *Arthritis Rheum* 43:238.
167. Maini, R., E. W. St Clair, F. Breedveld, D. Furst, J. Kalden, M. Weisman, J. Smolen, P. Emery, G. Harriman, M. Feldmann, and P. Lipsky. 1999. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. *Lancet* 354:1932-1939.
168. Kern, P., W. Kolowos, M. Hagenhofer, C. Frank, J. R. Kalden, and M. Herrmann. 1999. Alternatively spliced mRNA molecules of the thrombospondin receptor (CD36) in human PBMC. *Eur J Immunogenet* 26:337-342.
169. Antoni, C., and J. R. Kalden. 1999. Combination therapy of the chimeric monoclonal anti-tumor necrosis factor alpha antibody (infliximab) with methotrexate in patients with rheumatoid arthritis. *Clin Exp Rheumatol* 17:S73-77.
170. Furst, D. E., F. C. Breedveld, G. R. Burmester, L. Crofford, P. Emery, M. Feldman, J. R. Kalden, A. Kavanaugh, E. Keystone, P. E. Lipsky, R. N. Maini, L. Moreland, J. S. Smolen, L. Van De Putte, T. Vischer, M. Weinblatt, and M. Weissman. 1999. Access to disease modifying treatments for rheumatoid arthritis patients. *Ann Rheum Dis* 58 Suppl 1:I129-130.
171. Breedveld, F. C., J. R. Kalden, and J. S. Smolen. 1999. Advances in targeted therapies: TNFalpha blockade in clinical practice. *Ann Rheum Dis* 58 Suppl 1:I1.
172. Furst, D. E., F. C. Breedveld, J. R. Kalden, and J. S. Smolen. 1999. Building towards a consensus for the use of tumour necrosis factor blocking agents. *Ann Rheum Dis* 58:725-726.
173. Swaak, A. J., H. G. van den Brink, R. J. Smeenk, K. Manger, J. R. Kalden, S. Tosi, A. Marchesoni, Z. Domljan, B. Rozman, D. Logar, G. Pokorny, L. Kovacs, A. Kovacs, P. G. Vlachoyiannopoulos, H. M. Moutsopoulos, H. Chwalinska-Sadowska, B. Dratwianka, E. Kiss, N. Cikes, A. Branimir, M. Schneider, R. Fischer, S. Bombardieri, M. Mosca, J. S. Smolen, and et al. 1999. Systemic lupus erythematosus: clinical features in patients with a disease duration of over 10 years, first evaluation. *Rheumatology (Oxford)* 38:953-958.
174. Bohm, B. B., T. Aigner, A. Gehrsitz, C. P. Blobel, J. R. Kalden, and H. Burkhardt. 1999. Up-regulation of MDC15 (metargidin) messenger RNA in human osteoarthritic cartilage. *Arthritis Rheum* 42:1946-1950.
175. Lorenz, H. M., and J. R. Kalden. 1999. [Cytokines and mediators as therapeutic approaches]. *Internist (Berl)* 40:945-950.

176. Grunke, M., C. Dechant, P. Low, A. Rascu, J. R. Kalden, and T. Harrer. 1999. Hydroxyurea as part of a salvage regimen for heavily pretreated patients with advanced HIV infection. *J Acquir Immune Defic Syndr* 21:424-426.
177. Spriewald, B. M., A. Rascu, K. H. Schaller, J. Angerer, J. R. Kalden, and T. Harrer. 1999. Lead induced anaemia due to traditional Indian medicine: a case report. *Occup Environ Med* 56:282-283.
178. Charles, P., M. J. Elliott, D. Davis, A. Potter, J. R. Kalden, C. Antoni, F. C. Breedveld, J. S. Smolen, G. Eberl, K. deWoody, M. Feldmann, and R. N. Maini. 1999. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. *J Immunol* 163:1521-1528.
179. Rascu, A., H. G. Kraetsch, M. Grunke, J. R. Kalden, and B. Manger. 1999. [An unusual case of Heberden arthrosis in a young man]. *Z Rheumatol* 58:95-99.
180. Skapenko, A., J. Wendler, P. E. Lipsky, J. R. Kalden, and H. Schulze-Koops. 1999. Altered memory T cell differentiation in patients with early rheumatoid arthritis. *J Immunol* 163:491-499.
181. Voll, R. E., A. Mikulowska, J. R. Kalden, and R. Holmdahl. 1999. Amelioration of type II collagen induced arthritis in rats by treatment with sodium diethyldithiocarbamate. *J Rheumatol* 26:1352-1358
182. Kolowos, W., M. Schmitt, M. Herrman, E. Harrer, P. Low, J. R. Kalden, and T. Harrer. 1999. Biased TCR repertoire in HIV-1-infected patients due to clonal expansion of HIV-1-reverse transcriptase-specific CTL clones. *J Immunol* 162:7525-7533.
183. Lorenz, H. M., and J. R. Kalden. 1999. Biologic agents in the treatment of inflammatory rheumatic diseases. *Curr Opin Rheumatol* 11:179-184.
184. Blank, N. M., H. Steininger, J. R. Kalden, and H. Burkhardt. 1999. Symptomatic bone lesion of the tibia head as onset manifestation of sarcoidosis. *J Rheumatol* 26:936-937.
185. Landgraf, S., C. Dechant, B. Manger, and J. Kalden. 1999. [Lyme borreliosis: current status of diagnosis and therapy]. *Med Klin (Munich)* 94:105-108.
186. Alsalameh, S., K. Winter, R. Al-Ward, J. Wendler, J. R. Kalden, and R. W. Kinne. 1999. Distribution of TNF-alpha, TNF-R55 and TNF-R75 in the rheumatoid synovial membrane: TNF receptors are localized preferentially in the lining layer; TNF-alpha is distributed mainly in the vicinity of TNF receptors in the deeper layers. *Scand J Immunol* 49:278-285.
187. Wagner, R., B. Leschonsky, E. Harrer, C. Paulus, C. Weber, B. D. Walker, S. Buchbinder, H. Wolf, J. R. Kalden, and T. Harrer. 1999. Molecular and functional analysis of a conserved CTL epitope in HIV-1 p24 recognized from a long-term nonprogressor: constraints on immune escape associated with targeting a sequence essential for viral replication. *J Immunol* 162:3727-3734.
188. Alsalameh, S., B. Mattka, R. Al-Ward, H. M. Lorenz, B. Manger, K. Pfizenmaier, M. Grell, and J. R. Kalden. 1999. Preferential expression of tumor necrosis factor receptor 55 (TNF-R55) on human articular chondrocytes: selective transcriptional upregulation of TNF-R75 by proinflammatory cytokines interleukin 1beta, tumor necrosis factor-alpha, and basis fibroblast growth factor. *J Rheumatol* 26:645-653.

189. Tan, E. M., J. S. Smolen, J. S. McDougal, B. T. Butcher, D. Conn, R. Dawkins, M. J. Fritzler, T. Gordon, J. A. Hardin, J. R. Kalden, R. G. Lahita, R. N. Maini, N. F. Rothfield, R. Smeenk, Y. Takasaki, W. J. van Venrooij, A. Wiik, M. Wilson, and J. A. Koziol. 1999. A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity. *Arthritis Rheum* 42:455-464.
190. Smolen, J. S., J. R. Kalden, D. L. Scott, B. Rozman, T. K. Kvien, A. Larsen, I. Loew-Friedrich, C. Oed, and R. Rosenburg. 1999. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. *Lancet* 353:259-266.
191. Harrer, T., J. Schwab, W. G. Struff, M. Schmitt, J. H. Ficker, W. Rodl, H. Parsch, J. R. Kalden, and M. Gramatzki. 1998. Intralymphatic interleukin-2 in combination with zidovudine for the therapy of patients with AIDS. *Infection* 26:368-374.
192. Nagel, T., J. R. Kalden, and B. Manger. 1998. [Regulation of T-cell activation by CD28 and CTLA-4]. *Med Klin (Munich)* 93:592-597.
193. Gramatzki, M., W. D. Ludwig, R. Burger, P. Moos, P. Rohwer, C. Grunert, A. Sendler, J. R. Kalden, R. Andreesen, F. Henschke, and G. Moldenhauer. 1998. Antibodies TC-12 ("unique") and TH-111 (CD96) characterize T-cell acute lymphoblastic leukemia and a subgroup of acute myeloid leukemia. *Exp Hematol* 26:1209-1214.
194. Witte, T., K. Hartung, C. Sachse, T. Matthias, M. Fricke, H. Deicher, J. R. Kalden, H. J. Lakomek, H. H. Peter, and R. E. Schmidt. 1998. IgM anti-dsDNA antibodies in systemic lupus erythematosus: negative association with nephritis. SLE Study Group. *Rheumatol Int* 18:85-91.
195. Harrer, T., E. Harrer, P. Barbosa, F. Kaufmann, R. Wagner, S. Bruggemann, J. R. Kalden, M. Feinberg, R. P. Johnson, S. Buchbinder, and B. D. Walker. 1998. Recognition of two overlapping CTL epitopes in HIV-1 p17 by CTL from a long-term nonprogressing HIV-1-infected individual. *J Immunol* 161:4875-4881.
196. Witte, T., K. Hartung, T. Matthias, C. Sachse, M. Fricke, H. Deicher, J. R. Kalden, H. J. Lakomek, H. H. Peter, and R. E. Schmidt. 1998. Association of IgA anti-dsDNA antibodies with vasculitis and disease activity in systemic lupus erythematosus. SLE Study Group. *Rheumatol Int* 18:63-69.
197. Low, P., F. Neipel, A. Rascu, H. Steininger, B. Manger, B. Fleckenstein, J. R. Kalden, and T. Harrer. 1998. Suppression of HHV-8 viremia by foscarnet in an HIV-infected patient with Kaposi's sarcoma and HHV-8 associated hemophagocytic syndrome. *Eur J Med Res* 3:461-464.
198. Maini, R. N., F. C. Breedveld, J. R. Kalden, J. S. Smolen, D. Davis, J. D. Macfarlane, C. Antoni, B. Leeb, M. J. Elliott, J. N. Woody, T. F. Schaible, and M. Feldmann. 1998. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. *Arthritis Rheum* 41:1552-1563.
199. Kinne, R. W., P. Meyer, W. Grunder, E. Buchner, E. Palombo-Kinne, R. Heinzl-Wieland, W. Becker, F. Wolf, J. R. Kalden, and H. Burkhardt. 1998. Rat antigen-induced arthritis: cartilage alterations assessed with iodine-123-antileukoprotease. *J Nucl Med* 39:1638-1645.
200. Herrmann, M., M. Neidhart, S. Gay, M. Hagenhofer, and J. R. Kalden. 1998. Retrovirus-associated rheumatic syndromes. *Curr Opin Rheumatol* 10:347-354.

201. Lorenz, H. M., A. S. Lagoo, S. A. Lagoo-Deenadlayan, W. H. Barber, J. R. Kalden, and K. J. Hardy. 1998. Epitope-specific signaling through CD45 on T lymphocytes leads to cAMP synthesis in monocytes after ICAM-1-dependent cellular interaction. *Eur J Immunol* 28:2300-2310.
202. Grunke, M., H. G. Kraetsch, P. Low, A. Rascu, J. R. Kalden, and T. Harrer. 1998. Nelfinavir associated with peripheral neuropathy in an HIV-infected patient. *Infection* 26:252.
203. Kalden, J. 1998. New trends in immunoassay methodology. *Clin Chem Lab Med* 36:339-340.
204. Rosler, W., B. Manger, R. Repp, J. R. Kalden, and M. Gramatzki. 1998. Autologous PBPC in a patient with lymphoma and Sjogren's syndrome: complete remission of lymphoma without control of the autoimmune disease. *Bone Marrow Transplant* 22:211-213.
205. Kalden, J. R., T. Geiler, M. Herrmann, and W. Bertling. 1998. [Gene therapy in rheumatoid arthritis--an already feasible therapeutic principle?]. *Z Rheumatol* 57:139-146.
206. Mahler, V., C. Antoni, G. J. Anhalt, H. J. Koch, K. P. Peters, B. Manger, J. R. Kalden, and O. P. Hornstein. 1998. Graft-versus-host-like mucocutaneous eruptions with serological features of paraneoplastic pemphigus and systemic lupus erythematosus in a patient with non-Hodgkin's lymphoma. *Dermatology* 197:78-83.
207. Wurflein, D., M. Dechant, B. Stockmeyer, A. L. Tutt, P. Hu, R. Repp, J. R. Kalden, J. G. van de Winkel, A. L. Epstein, T. Valerius, M. Glennie, and M. Gramatzki. 1998. Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells. *Cancer Res* 58:3051-3058.
208. Spriewald, B. M., R. Wassmuth, H. D. Carl, F. Kockerling, S. Reichstetter, A. Kleeberger, M. Klein, M. W. Hohenberger, and J. R. Kalden. 1998. Microchimerism after liver transplantation: prevalence and methodological aspects of detection. *Transplantation* 66:77-83.
209. Herrmann, M., R. E. Voll, O. M. Zoller, M. Hagenhofer, B. B. Ponner, and J. R. Kalden. 1998. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. *Arthritis Rheum* 41:1241-1250.
210. Manger, K., R. Repp, B. M. Spriewald, A. Rascu, A. Geiger, R. Wassmuth, N. A. Westerdaal, B. Wentz, B. Manger, J. R. Kalden, and J. G. van de Winkel. 1998. Fcγ receptor IIa polymorphism in Caucasian patients with systemic lupus erythematosus: association with clinical symptoms. *Arthritis Rheum* 41:1181-1189.
211. Kalden, J. R., and B. Manger. 1998. Biologic agents in the treatment of inflammatory rheumatic diseases. *Curr Opin Rheumatol* 10:174-178.
212. Ponner, B. B., C. Stach, O. Zoller, M. Hagenhofer, R. Voll, J. R. Kalden, and M. Herrmann. 1998. Induction of apoptosis reduces immunogenicity of human T-cell lines in mice. *Scand J Immunol* 47:343-347.
213. Manger, K., and J. R. Kalden. 1998. [Gastritis and thoracic pain. Churg-Strauss vasculitis]. *Med Klin (Munich)* 93:190.
214. Alsalameh, S., B. Manger, P. Kern, and J. Kalden. 1998. New onset of rheumatoid arthritis during interferon beta-1B treatment in a patient with multiple sclerosis: comment on the case report by Jabaily and Thompson. *Arthritis Rheum* 41:754.
215. Burger, R., F. Neipel, B. Fleckenstein, R. Savino, G. Ciliberto, J. R. Kalden, and M. Gramatzki. 1998. Human herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cells. *Blood* 91:1858-1863.

216. Kalden, J. R., F. C. Breedveld, H. Burkhardt, and G. R. Burmester. 1998. Immunological treatment of autoimmune diseases. *Adv Immunol* 68:333-418.
217. Kraetsch, H. G., A. Rascu, J. R. Kalden, and B. Manger. 1997. [Clinical course and prognostic parameters in adult-onset Still's syndrome. Own experience and review of the literature]. *Med Klin (Munich)* 92:705-711.
218. Kalden, J. R., and J. Sieper. 1998. Oral collagen in the treatment of rheumatoid arthritis. *Arthritis Rheum* 41:191-194.
219. Schulte, S., C. Unger, J. A. Mo, O. Wendler, E. Bauer, S. Frischholz, K. von der Mark, J. R. Kalden, R. Holmdahl, and H. Burkhardt. 1998. Arthritis-related B cell epitopes in collagen II are conformation-dependent and sterically privileged in accessible sites of cartilage collagen fibrils. *J Biol Chem* 273:1551-1561.
220. Valerius, T., D. Wurflein, B. Stockmeyer, R. Repp, J. R. Kalden, and M. Gramatzki. 1997. Activated neutrophils as effector cells for bispecific antibodies. *Cancer Immunol Immunother* 45:142-145.
221. Voll, R. E., E. A. Roth, I. Girkontaite, H. Fehr, M. Herrmann, H. M. Lorenz, and J. R. Kalden. 1997. Histone-specific Th0 and Th1 clones derived from systemic lupus erythematosus patients induce double-stranded DNA antibody production. *Arthritis Rheum* 40:2162-2171.
222. Kolowos, W., M. Herrmann, B. B. Ponner, R. Voll, P. Kern, C. Frank, and J. R. Kalden. 1997. Detection of restricted junctional diversity of peripheral T cells in SLE patients by spectratyping. *Lupus* 6:701-707.
223. Valerius, T., B. Stockmeyer, A. B. van Spriel, R. F. Graziano, I. E. van den Herik-Oudijk, R. Repp, Y. M. Deo, J. Lund, J. R. Kalden, M. Gramatzki, and J. G. van de Winkel. 1997. Fc α RI (CD89) as a novel trigger molecule for bispecific antibody therapy. *Blood* 90:4485-4492.
224. Grunke, M., T. Valerius, B. Manger, J. R. Kalden, and T. Harrer. 1997. Renal dysfunction in a human immunodeficiency virus-infected patient who was treated with indinavir. *Clin Infect Dis* 25:1270-1271.
225. Voll, R. E., M. Herrmann, E. A. Roth, C. Stach, J. R. Kalden, and I. Girkontaite. 1997. Immunosuppressive effects of apoptotic cells. *Nature* 390:350-351.
226. Burkhardt, H., and J. R. Kalden. 1997. Animal models of autoimmune diseases. *Rheumatol Int* 17:91-99.
227. Burkhardt, H., and J. R. Kalden. 1997. Xenobiotic immunosuppressive agents: therapeutic effects in animal models of autoimmune diseases. *Rheumatol Int* 17:85-90.
228. Zollner, R. C., P. Kern, H. Steininger, J. R. Kalden, and B. Manger. 1997. [Hyperferritinemia in Still syndrome in the adult and reactive hemophagocytic syndrome]. *Med Klin (Munich)* 92:494-498.
229. Tan, E. M., T. E. Feltkamp, J. S. Smolen, B. Butcher, R. Dawkins, M. J. Fritzler, T. Gordon, J. A. Hardin, J. R. Kalden, R. G. Lahita, R. N. Maini, J. S. McDougal, N. F. Rothfield, R. J. Smeenk, Y. Takasaki, A. Wiik, M. R. Wilson, and J. A. Koziol. 1997. Range of antinuclear antibodies in "healthy" individuals. *Arthritis Rheum* 40:1601-1611.

230. Cook, P. M., T. F. Schulz, A. Rascu, J. R. Kalden, and T. Harrer. 1997. Lack of serologic evidence for involvement of human herpesvirus 8 in autoimmune diseases. *Arthritis Rheum* 40:1906-1907.
231. Leiberich, P., M. Engeter, E. Olbrich, A. Rubbert, K. Schumacher, M. Brieger, J. R. Kalden, and P. Joraschky. 1997. Longitudinal development of distress, coping and quality of life in HIV-positive persons. *Psychother Psychosom* 66:237-247.
232. Geiler, T., H. M. Lorenz, J. R. Kalden, and B. Manger. 1997. [Pathogenesis of rheumatoid arthritis]. *Med Klin (Munich)* 92:347-353.
233. Kalden, J. R. 1997. Defective phagocytosis of apoptotic cells: possible explanation for the induction of autoantibodies in SLE. *Lupus* 6:326-327.
234. Low, P., C. Weber, E. Harrer, P. Rohwer, J. R. Kalden, and T. Harrer. 1997. CD80 expression on monocytes in HIV-infected patients. *J Acquir Immune Defic Syndr Hum Retrovirol* 15:264-268.
235. Lorenz, H. M., T. Geiler, and J. R. Kalden. 1997. [Immunosuppressive therapeutic modalities in chronic polyarthritis]. *Internist (Berl)* 38:532-540.
236. Lorenz, H. M., T. Hieronymus, M. Grunke, B. Manger, and J. R. Kalden. 1997. Differential role for IL-2 and IL-15 in the inhibition of apoptosis in short-term activated human lymphocytes. *Scand J Immunol* 45:660-669.
237. Burkhardt, H., P. Meyer, E. Buchner, E. Palombo-Kinne, R. Heinzl-Wieland, W. Becker, F. Wolf, J. R. Kalden, and R. W. Kinne. 1997. The serine proteinase inhibitor antileukoproteinase specifically accumulates in normal but not in arthritic cartilage. *J Rheumatol* 24:1145-1154.
238. Kalden, J. R. 1997. Rescue of DMARD failures by means of monoclonal antibodies or biological agents. *Clin Exp Rheumatol* 15 Suppl 17:S91-98.
239. Kalden, J. R., and B. Manger. 1997. Biologic agents in the treatment of inflammatory rheumatic diseases. *Curr Opin Rheumatol* 9:206-212.
240. Rascu, A., R. Repp, N. A. Westerdaal, J. R. Kalden, and J. G. van de Winkel. 1997. Clinical relevance of Fc gamma receptor polymorphisms. *Ann N Y Acad Sci* 815:282-295.
241. Manger, B., and J. R. Kalden. 1997. [Mediastinal spreading and aortic insufficiency]. *Med Klin (Munich)* 92:144.
242. Smolen, J. S., B. Butcher, M. J. Fritzler, T. Gordon, J. Hardin, J. R. Kalden, R. Lahita, R. N. Maini, W. Reeves, M. Reichlin, N. Rothfield, Y. Takasaki, W. J. van Venrooij, and E. M. Tan. 1997. Reference sera for antinuclear antibodies. II. Further definition of antibody specificities in international antinuclear antibody reference sera by immunofluorescence and western blotting. *Arthritis Rheum* 40:413-418.
243. Stockmeyer, B., T. Valerius, R. Repp, I. A. Heijnen, H. J. Buhning, Y. M. Deo, J. R. Kalden, M. Gramatzki, and J. G. van de Winkel. 1997. Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer. *Cancer Res* 57:696-701.
244. Wagner, U., S. Kaltenhauser, H. Sauer, S. Arnold, W. Seidel, H. Hantzschel, J. R. Kalden, and R. Wassmuth. 1997. HLA markers and prediction of clinical course and outcome in rheumatoid arthritis. *Arthritis Rheum* 40:341-351.

245. Lorenz, H. M., M. Grunke, T. Hieronymus, M. Herrmann, A. Kuhnel, B. Manger, and J. R. Kalden. 1997. In vitro apoptosis and expression of apoptosis-related molecules in lymphocytes from patients with systemic lupus erythematosus and other autoimmune diseases. *Arthritis Rheum* 40:306-317.
246. Meusser, S., G. Eger, M. Anders, H. Burkhardt, and J. R. Kalden. 1997. [Manifestation of neuro-Behcet disease in cyclosporin A therapy]. *Z Rheumatol* 56:31-39.
247. Kalden-Nemeth, D., J. Grebmeier, C. Antoni, B. Manger, F. Wolf, and J. R. Kalden. 1997. NMR monitoring of rheumatoid arthritis patients receiving anti-TNF-alpha monoclonal antibody therapy. *Rheumatol Int* 16:249-255.
248. Tsuzaka, K., T. H. Winkler, J. R. Kalden, and M. Reichlin. 1996. Autoantibodies to double-stranded (ds)DNA immunoprecipitate 18S ribosomal RNA by virtue of their interaction with ribosomal protein S1 and suppress in vitro protein synthesis. *Clin Exp Immunol* 106:504-508.
249. Reichstetter, S., G. Brunner, J. R. Kalden, and R. Wassmuth. 1996. DQB1 promoter sequence variability and linkage in caucasoids. *Hum Immunol* 51:73-80.
250. Stuhlmuller, B., R. Jerez, G. Hausdorf, H. R. Barthel, M. Meurer, E. Genth, J. R. Kalden, and G. R. Burmester. 1996. Novel autoantibodies against muscle-cell membrane proteins in patients with myositis. *Arthritis Rheum* 39:1860-1868.
251. Baum, W., H. Steininger, H. J. Bair, W. Becker, T. E. Hansen-Hagge, M. Kressel, E. Kremmer, J. R. Kalden, and M. Gramatzki. 1996. Therapy with CD7 monoclonal antibody TH-69 is highly effective for xenografted human T-cell ALL. *Br J Haematol* 95:327-338.
252. Hain, N. A., B. Stuhlmuller, G. R. Hahn, J. R. Kalden, R. Deutzmann, and G. R. Burmester. 1996. Biochemical characterization and microsequencing of a 205-kDa synovial protein stimulatory for T cells and reactive with rheumatoid factor containing sera. *J Immunol* 157:1773-1780.
253. Herrmann, M., M. Hagenhofer, and J. R. Kalden. 1996. Retroviruses and systemic lupus erythematosus. *Immunol Rev* 152:145-156.
254. Rascu, A., K. Manger, H. G. Kraetsch, J. R. Kalden, and B. Manger. 1996. Osteonecrosis in systemic lupus erythematosus, steroid-induced or a lupus-dependent manifestation? *Lupus* 5:323-327.
255. Manger, K., J. R. Kalden, and B. Manger. 1996. Cyclosporin A in the treatment of systemic lupus erythematosus: results of an open clinical study. *Br J Rheumatol* 35:669-675.
256. Kalden, J. R., and B. Manger. 1996. Biologic agents in the treatment of inflammatory rheumatic diseases. *Curr Opin Rheumatol* 8:195-200.
257. Aupperle, K. R., S. Alsalameh, K. P. Stock, G. R. Burmester, and J. R. Kalden. 1996. [Comparison of rheumatoid test procedures--value and critical interpretation of sensitivity and specificity and their effect on pre-test and post-test probability]. *Z Rheumatol* 55:158-167.
258. Elsasser, D., T. Valerius, R. Repp, G. J. Weiner, Y. Deo, J. R. Kalden, J. G. van de Winkel, G. T. Stevenson, M. J. Glennie, and M. Gramatzki. 1996. HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor. *Blood* 87:3803-3812.

259. Nusslein, H. G., K. H. Frosch, W. Woith, P. Lane, J. R. Kalden, and B. Manger. 1996. Increase of intracellular calcium is the essential signal for the expression of CD40 ligand. *Eur J Immunol* 26:846-850.
260. Tsuzaka, K., A. K. Leu, M. B. Frank, B. F. Movafagh, M. Koscec, T. H. Winkler, J. R. Kalden, and M. Reichlin. 1996. Lupus autoantibodies to double-stranded DNA cross-react with ribosomal protein S1. *J Immunol* 156:1668-1675.
261. Lorenz, H. M., C. Antoni, T. Valerius, R. Repp, M. Grunke, N. Schwerdtner, H. Nusslein, J. Woody, J. R. Kalden, and B. Manger. 1996. In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects. *J Immunol* 156:1646-1653.
262. Herrmann, M., O. M. Zoller, M. Hagenhofer, R. Voll, and J. R. Kalden. 1996. What triggers anti-dsDNA antibodies? *Mol Biol Rep* 23:265-267.
263. Meusser, S., A. Rubbert, B. Manger, E. Bock, G. Platsch, H. Feistel, A. Engelhardt, F. Wolf, and J. R. Kalden. 1996. 99m-Tc-HMPAO-SPECT in diagnosis of early cerebral vasculitis. *Rheumatol Int* 16:37-42.
264. Kalden, J. R. 1996. Pathogenic aspects of systemic lupus erythematosus. *Isr J Med Sci* 32:3-6.
265. Becker, W. S., T. M. Behr, F. Cumme, W. Rossler, J. Wendler, P. M. Kern, M. Gramatzki, J. R. Kalden, D. M. Goldenberg, and F. G. Wolf. 1995. 67Ga citrate versus 99mTc-labeled LL2-Fab' (anti-CD22) fragments in the staging of B-cell non-Hodgkin's lymphoma. *Cancer Res* 55:5771s-5773s.
266. Kalden, J. R. 1995. [Virus-induced arthritis]. *Z Rheumatol* 54:389-390.
267. Meusser, S., R. Beck, B. Fleckenstein, and J. R. Kalden. 1995. [25-year-old patient with pancytopenia]. *Internist (Berl)* 36:999-1004.
268. Ehrenstein, M. R., D. R. Katz, M. H. Griffiths, L. Papadaki, T. H. Winkler, J. R. Kalden, and D. A. Isenberg. 1995. Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. *Kidney Int* 48:705-711.
269. Herrmann, M., T. H. Winkler, H. Fehr, and J. R. Kalden. 1995. Preferential recognition of specific DNA motifs by anti-double-stranded DNA autoantibodies. *Eur J Immunol* 25:1897-1904.
270. Manger, B., and J. R. Kalden. 1995. Joint and connective tissue ultrasonography--a rheumatologic bedside procedure? A German experience. *Arthritis Rheum* 38:736-742.
271. Kalden, J. R., and B. Manger. 1995. Biologic agents in the treatment of inflammatory rheumatic diseases. *Curr Opin Rheumatol* 7:191-197.
272. Kalden, J. R., and B. Manger. 1995. New therapeutic approaches in autoimmune rheumatic diseases, with special emphasis on rheumatoid arthritis. *Br J Rheumatol* 34:193-196.
273. Sachse, C., K. Luthke, K. Hartung, M. Fricke, B. Liedvogel, J. R. Kalden, H. H. Peter, H. J. Lakomek, E. Henkel, and H. Deicher. 1995. Significance of antibodies to cardiolipin in unselected patients with systemic lupus erythematosus: clinical and laboratory associations. The SLE Study Group. *Rheumatol Int* 15:23-29.

274. Herrmann, M., H. M. Lorenz, R. Voll, M. Grunke, W. Woith, and J. R. Kalden. 1994. A rapid and simple method for the isolation of apoptotic DNA fragments. *Nucleic Acids Res* 22:5506-5507.
275. Rubbert, A., E. Bock, J. Schwab, J. Marienhagen, H. Nusslein, F. Wolf, and J. R. Kalden. 1994. Anticardiolipin antibodies in HIV infection: association with cerebral perfusion defects as detected by 99mTc-HMPAO SPECT. *Clin Exp Immunol* 98:361-368.
276. Klebl, F. H., G. Weber, J. R. Kalden, and H. G. Nusslein. 1994. In vitro and in vivo effect of glucocorticoids on IgE and IgG subclass secretion. *Clin Exp Allergy* 24:1022-1029.
277. Kalden, J. R. 1994. Anti-CD4 treatment of patients with rheumatoid arthritis. Is there still a place for this treatment principle in RA? *Clin Exp Rheumatol* 12 Suppl 11:S67-69.
278. Elliott, M. J., R. N. Maini, M. Feldmann, J. R. Kalden, C. Antoni, J. S. Smolen, B. Leeb, F. C. Breedveld, J. D. Macfarlane, H. Bijl, and et al. 1994. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. *Lancet* 344:1105-1110.
279. Kalden, J. R., and S. Gay. 1994. Retroviruses and autoimmune rheumatic diseases. *Clin Exp Immunol* 98:1-5.
280. Burger, R., J. Wendler, K. Antoni, G. Helm, J. R. Kalden, and M. Gramatzki. 1994. Interleukin-6 production in B-cell neoplasias and Castleman's disease: evidence for an additional paracrine loop. *Ann Hematol* 69:25-31.
281. Alsalameh, S., G. S. Firestein, S. Oez, R. Kurrle, J. R. Kalden, and G. R. Burmester. 1994. Regulation of granulocyte macrophage colony stimulating factor production by human articular chondrocytes. Induction by both tumor necrosis factor-alpha and interleukin 1, downregulation by transforming growth factor beta and upregulation by fibroblast growth factor. *J Rheumatol* 21:993-1002.
282. Nusslein, H. G., G. Weber, and J. R. Kalden. 1994. Synthetic glucocorticoids potentiate IgE synthesis. Influence of steroid and nonsteroid hormones on human in vitro IgE secretion. *Allergy* 49:365-370.
283. Kalden, J. R. 1994. Biologic agents in the therapy of inflammatory rheumatic diseases, including therapeutic antibodies, cytokines, and cytokine antagonists. *Curr Opin Rheumatol* 6:281-286.
284. Arenander, H., R. Ruppert, J. R. Kalden, and W. Rodl. 1994. [An unusual case of rectal-sigmoid varicose veins in portal vein thrombosis]. *Rontgenpraxis* 47:148-149.
285. Winkler, T. H., and J. R. Kalden. 1994. Origin of anti-DNA autoantibodies in SLE. *Lupus* 3:75-76.
286. Keyna, U., E. Platzer, W. Woith, I. Nusslein, J. R. Kalden, and B. Manger. 1994. Differential effects of transferrin receptor antibodies on growth and receptor expression of human lymphocytic and myelocytic cell lines. *Eur J Haematol* 52:169-175.
287. Herrmann, M., and J. R. Kalden. 1994. PCR and reverse dot hybridization for the detection of endogenous retroviral transcripts. *J Virol Methods* 46:333-348.
288. Stuhlmuller, B., I. Kalies, H. Kachelries, K. F. Druschky, and J. R. Kalden. 1994. Characterization of a 58- and a 78-kD monocytic membrane protein with affinity to the acetylcholine receptor in myasthenia gravis patients. *Scand J Immunol* 39:305-313.

289. Kinne, R. W., W. Becker, J. Schwab, A. Schwarz, J. R. Kalden, F. Emmrich, G. R. Burmester, and F. Wolf. 1994. Imaging rheumatoid arthritis joints with technetium-99m labelled specific anti-CD4- and non-specific monoclonal antibodies. *Eur J Nucl Med* 21:176-180.
290. Reichstetter, S., P. H. Krellner, C. M. Meenzen, J. R. Kalden, and R. Wassmuth. 1994. Comparative analysis of sequence variability in the upstream regulatory region of the HLA-DQB1 gene. *Immunogenetics* 39:207-212.
291. Jahn, S., B. Niemann, T. Winkler, J. R. Kalden, and R. von Baehr. 1994. Expansion of a B-lymphocyte clone producing IgM auto-antibodies encoded by a somatically mutated VHI gene in the spleen of an autoimmune patient. *Rheumatol Int* 13:187-196.
292. Pirner, K., A. Rascu, W. Nurnberg, A. Rubbert, J. R. Kalden, and B. Manger. 1994. Evidence for direct anti-heparin-sulphate reactivity in sera of SLE patients. *Rheumatol Int* 14:169-174.
293. Alsalameh, S., G. R. Burmester, and J. R. Kalden. 1994. Basic mechanisms in rheumatoid arthritis: the role of T lymphocytes in rheumatoid synovitis. *Adv Prostaglandin Thromboxane Leukot Res* 22:289-304.
294. De Carli, M., S. Berthold, H. Fickenscher, I. M. Fleckenstein, M. M. D'Elios, Q. Gao, R. Biagiotti, M. G. Giudizi, J. R. Kalden, B. Fleckenstein, and et al. 1993. Immortalization with herpesvirus saimiri modulates the cytokine secretion profile of established Th1 and Th2 human T cell clones. *J Immunol* 151:5022-5030.
295. Nusslein, H. G., A. Dietz, R. Burger, T. Trag, J. R. Kalden, and M. Gramatzki. 1993. Chronic lymphocytic leukemia cells induce non-T cells to produce IgE in the presence of interleukin-4. *J Clin Immunol* 13:397-405.
296. Haupl, T., G. Hahn, M. Rittig, A. Krause, C. Schoerner, U. Schonherr, J. R. Kalden, and G. R. Burmester. 1993. Persistence of *Borrelia burgdorferi* in ligamentous tissue from a patient with chronic Lyme borreliosis. *Arthritis Rheum* 36:1621-1626.
297. Nagel, T., G. Eger, J. R. Kalden, and B. Manger. 1993. [Arthroostitis pustulosa, spondylarthritis hyperostotica pustulo-psoriatica, SAPHO syndrome: clinical experiences and review of the literature]. *Z Rheumatol* 52:390-397.
298. Wassmuth, R., S. Eastman, I. Kockum, E. Holmberg, M. Starck, T. Lindhagen, J. R. Kalden, A. Lernmark, G. Sundkvist, and S. Lindgren. 1993. HLA DR and DQ RFLP analysis in Crohn's disease. *Eur J Immunogenet* 20:429-433.
299. Stuhlmuller, B., J. R. Kalden, R. Fahlbusch, N. Hain, and B. Manger. 1993. Immunological and functional properties of the acetylcholine receptor expressed on the human cell line TE671. *Eur J Clin Chem Clin Biochem* 31:657-665.
300. Rubbert, A., J. Marienhagen, K. Pirner, B. Manger, J. Grebmeier, A. Engelhardt, F. Wolf, and J. R. Kalden. 1993. Single-photon-emission computed tomography analysis of cerebral blood flow in the evaluation of central nervous system involvement in patients with systemic lupus erythematosus. *Arthritis Rheum* 36:1253-1262.
301. Kinne, R. W., W. Becker, J. Schwab, G. Horneff, A. Schwarz, J. R. Kalden, F. Emmrich, G. R. Burmester, and F. Wolf. 1993. Comparison of ⁹⁹Tcm-labelled specific murine anti-CD4 monoclonal antibodies and nonspecific human immunoglobulin for imaging inflamed joints in rheumatoid arthritis. *Nucl Med Commun* 14:667-675.

302. Alsalameh, S., J. Mollenhauer, F. Scheuplein, H. Stoss, J. R. Kalden, H. Burkhardt, and G. R. Burmester. 1993. Preferential cellular and humoral immune reactivities to native and denatured collagen types IX and XI in a patient with fatal relapsing polychondritis. *J Rheumatol* 20:1419-1424.
303. Valerius, T., R. Repp, T. P. de Wit, S. Berthold, E. Platzer, J. R. Kalden, M. Gramatzki, and J. G. van de Winkel. 1993. Involvement of the high-affinity receptor for IgG (Fc gamma RI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy. *Blood* 82:931-939.
304. Woith, W., I. Nusslein, C. Antoni, D. I. Dejica, T. H. Winkler, M. Herrmann, K. Pirner, J. R. Kalden, and B. Manger. 1993. A soluble form of the human transferrin receptor is released by activated lymphocytes in vitro. *Clin Exp Immunol* 92:537-542.
305. Pirner, K., A. Rubbert, G. R. Burmester, J. R. Kalden, and B. Manger. 1993. [Intravenous administration of immunoglobulins in systemic lupus erythematosus: review of the literature and initial clinical experiences]. *Infusionsther Transfusionsmed* 20 Suppl 1:131-135; discussion 136.
306. Horneff, G., J. Schwab, N. Holtz, J. R. Kalden, and G. R. Burmester. 1993. [High-dose immunoglobulin therapy of rheumatoid arthritis]. *Infusionsther Transfusionsmed* 20 Suppl 1:110-115; discussion 116-117.
307. Strobel, G., R. Schwarz, P. Heppt, B. Granz, J. R. Kalden, and B. Manger. 1993. [Use of an improved transmission ultrasound camera for diagnosis of rheumatic joint diseases]. *Z Rheumatol* 52:114-120.
308. Hahn, G., B. Stuhlmüller, N. Hain, J. R. Kalden, K. Pfizenmaier, and G. R. Burmester. 1993. Modulation of monocyte activation in patients with rheumatoid arthritis by leukapheresis therapy. *J Clin Invest* 91:862-870.
309. Lorenz, H. M., T. Harrer, A. S. Lagoo, A. Baur, G. Eger, and J. R. Kalden. 1993. CD45 mAb induces cell adhesion in peripheral blood mononuclear cells via lymphocyte function-associated antigen-1 (LFA-1) and intercellular cell adhesion molecule 1 (ICAM-1). *Cell Immunol* 147:110-128.
310. Horneff, G., U. Sack, J. R. Kalden, F. Emmrich, and G. R. Burmester. 1993. Reduction of monocyte-macrophage activation markers upon anti-CD4 treatment. Decreased levels of IL-1, IL-6, neopterin and soluble CD14 in patients with rheumatoid arthritis. *Clin Exp Immunol* 91:207-213.
311. Horneff, G., A. H. Guse, H. Schulze-Koops, J. R. Kalden, G. R. Burmester, and F. Emmrich. 1993. Human CD4 modulation in vivo induced by antibody treatment. *Clin Immunol Immunopathol* 66:80-90.
312. Kalden, J. R., and M. Herrmann. 1993. Autoimmune diseases in humans, e.g. autoimmune rheumatic diseases. *Intervirolgy* 35:176-185.
313. Bleil, L., T. H. Winkler, H. K. Fehr, E. K. Bautz, and J. R. Kalden. 1993. A new approach to the molecular characterization of the c-ANCA antigen in Wegener's granulomatosis. *Adv Exp Med Biol* 336:51-54.
314. Kalden, J. R. 1993. Interview with Joachim Robert Kalden. What is going to happen tomorrow as far as DNA and anti-DNA antibodies are concerned?. Interview by P. Youinou. *Ann Med Interne (Paris)* 144:463-464.

315. Leiberich, P., M. Aeverbeck, M. Grote-Kusch, A. Schroeder, E. Olbrich, and J. R. Kalden. 1993. [The quality of life of tumor patients as a multidimensional concept]. *Z Psychosom Med Psychoanal* 39:26-37.
316. Oez, S., J. Birkmann, and J. R. Kalden. 1993. Clonal growth of functionally normal and deficient neutrophils from the bone marrow of a patient with variant chronic granulomatous disease. Lack of reconstitution of oxidative burst defect by G-CSF, GM-CSF, and IFN-gamma in vitro. *Ann Hematol* 66:21-25.
317. Pedrollo, E., L. Bleil, F. A. Bautz, J. R. Kalden, and E. K. Bautz. 1993. Antineutrophil cytoplasmic autoantibodies (ANCA) recognizing a recombinant myeloperoxidase subunit. *Adv Exp Med Biol* 336:87-92.
318. Horneff, G., F. Emmrich, C. Reiter, J. R. Kalden, and G. R. Burmester. 1992. Persistent depletion of CD4+ T cells and inversion of the CD4/CD8 T cell ratio induced by anti-CD4 therapy. *J Rheumatol* 19:1845-1850.
319. Alsalameh, S., R. Jerez, J. Bujia, T. Haeupl, J. R. Kalden, and G. R. Burmester. 1992. [Role of cytokines and growth factors in joint destruction processes]. *Rev Med Chil* 120:1400-1410.
320. Nusslein, H. G., T. Trag, M. Winter, A. Dietz, and J. R. Kalden. 1992. The role of T cells and the effect of hydrocortisone on interleukin-4-induced IgE synthesis by non-T cells. *Clin Exp Immunol* 90:286-292.
321. Emmrich, F., G. Burmester, G. Horneff, J. Emmrich, P. Reinke, F. Hiepe, J. Kalden, H. Schulze-Koops, and H. D. Volk. 1992. [Treatment of autoimmune diseases and graft rejection with anti-CD4 antibodies]. *Z Gesamte Inn Med* 47:500-507.
322. Hartung, K., M. P. Baur, R. Coldewey, M. Fricke, J. R. Kalden, H. J. Lakomek, H. H. Peter, D. Schendel, P. M. Schneider, S. A. Seuchter, and et al. 1992. Major histocompatibility complex haplotypes and complement C4 alleles in systemic lupus erythematosus. Results of a multicenter study. *J Clin Invest* 90:1346-1351.
323. Rubbert, A., K. Pirner, L. Wildt, J. R. Kalden, and B. Manger. 1992. Pregnancy course and complications in patients with systemic lupus erythematosus. *Am J Reprod Immunol* 28:205-207.
324. Kalden, J. R. 1992. WHO/IUIS Standardization Programme. *Clin Exp Rheumatol* 10:513-514.
325. Harrer, T., B. Wolf, W. Nager, W. Schwarz, D. Bergner, and J. R. Kalden. 1992. In vitro activation of peripheral mononuclear cells by zinc in HIV-infected patients and healthy controls. *Clin Exp Immunol* 89:285-289.
326. Winkler, T. H., H. Fehr, and J. R. Kalden. 1992. Analysis of immunoglobulin variable region genes from human IgG anti-DNA hybridomas. *Eur J Immunol* 22:1719-1728.
327. Becker, W., G. Horneff, F. Emmrich, G. Burmester, J. Kalden, and F. Wolf. 1992. Kinetics of 99mTc-labelled antibodies against CD4 (T-helper) lymphocytes in man. *Nuklearmedizin* 31:84-90.
328. Kalden, J. R. 1992. Pathogenic aspects of systemic lupus erythematosus (SLE). *Behring Inst Mitt*:197-203.

329. Rubbert, A., K. Pirner, L. Wildt, J. R. Kalden, and B. Manger. 1992. [Systemic lupus erythematosus and pregnancy]. *Z Rheumatol* 51:78-86.
330. Pirner, K., A. Rubbert, R. Salinger, J. R. Kalden, and B. Manger. 1992. [Significance of ultraviolet light in the pathogenesis of systemic lupus erythematosus: case report and discussion of the literature]. *Z Rheumatol* 51:20-24.
331. Hartung, K., R. Coldewey, A. Corvetta, H. Deicher, J. R. Kalden, F. Krapf, B. Lang, H. J. Lakomek, B. Liedvogel, H. H. Peter, and et al. 1992. MHC gene products and anticardiolipin antibodies in systemic lupus erythematosus results of a multicenter study. SLE Study Group. *Autoimmunity* 13:95-99.
332. Herrmann, M., A. Baur, H. Nebel-Schickel, R. Vornhagen, G. Jahn, F. E. Krapf, and J. R. Kalden. 1992. Antibodies against p24 of HIV-1 in patients with systemic lupus erythematosus? *Viral Immunol* 5:229-231.
333. Ehrfeld, H., K. Hartung, M. Renz, R. Coldewey, H. Deicher, M. Fricke, J. R. Kalden, J. Lakomek, H. H. Peter, D. Schendel, and et al. 1992. MHC associations of autoantibodies against recombinant Ro and La proteins in systemic lupus erythematosus. Results of a multicenter study. SLE Study Group. *Rheumatol Int* 12:169-173.
334. Alsalameh, S., J. R. Kalden, and G. R. Burmester. 1991. [The role of cytokines and growth factors in rheumatoid joint destruction]. *Z Rheumatol* 50:347-359.
335. Baur, A., T. Harrer, M. Peukert, G. Jahn, J. R. Kalden, and B. Fleckenstein. 1991. Alpha-lipoic acid is an effective inhibitor of human immuno-deficiency virus (HIV-1) replication. *Klin Wochenschr* 69:722-724.
336. Winkler, T. H., S. Jahn, and J. R. Kalden. 1991. IgG human monoclonal anti-DNA autoantibodies from patients with systemic lupus erythematosus. *Clin Exp Immunol* 85:379-385.
337. Kalden, J. R., and F. Krapf. 1991. [Plasma nucleic acids and their possible pathophysiologic significance in systemic lupus erythematosus]. *Z Rheumatol* 50:297-303.
338. Rubbert, A., B. Manger, N. Lang, J. R. Kalden, and E. Platzer. 1991. Functional characterization of tumor-infiltrating lymphocytes, lymph-node lymphocytes and peripheral-blood lymphocytes from patients with breast cancer. *Int J Cancer* 49:25-31.
339. Repp, R., T. Valerius, A. Sandler, M. Gramatzki, H. Iro, J. R. Kalden, and E. Platzer. 1991. Neutrophils express the high affinity receptor for IgG (Fc gamma RI, CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor. *Blood* 78:885-889.
340. Bleil, L., B. Manger, T. H. Winkler, M. Herrman, G. R. Burmester, F. E. Krapf, and J. R. Kalden. 1991. The role of antineutrophil cytoplasm antibodies, anticardiolipin antibodies, von Willebrand factor antigen, and fibronectin for the diagnosis of systemic vasculitis. *J Rheumatol* 18:1199-1206.
341. Gramatzki, M., R. Burger, J. Kraus, U. Lauer, P. Rohwer, G. Eger, J. R. Kalden, and F. Henschke. 1991. Monoclonal antibodies EBU-141 (CDw75) and EBU-65 allow reliable distinction between mature and pre-B-cell tumors in suspension and on tissue sections. *Ann Hematol* 63:20-26.
342. Scheuerlein, J. G., I. Kalies, W. P. Gluth, and J. R. Kalden. 1991. Monoclonal antibodies monospecific to single-chain urokinase-type plasminogen activator (scu-PA). *Hybridoma* 10:395-399.

343. Horneff, G., A. Krause, F. Emmrich, J. R. Kalden, and G. R. Burmester. 1991. Elevated levels of circulating tumor necrosis factor-alpha, interferon-gamma, and interleukin-2 in systemic reactions induced by anti-CD4 therapy in patients with rheumatoid arthritis. *Cytokine* 3:266-267.
344. Horneff, G., T. Winkler, J. R. Kalden, F. Emmrich, and G. R. Burmester. 1991. Human anti-mouse antibody response induced by anti-CD4 monoclonal antibody therapy in patients with rheumatoid arthritis. *Clin Immunol Immunopathol* 59:89-103.
345. Krause, A., V. Brade, C. Schoerner, W. Solbach, J. R. Kalden, and G. R. Burmester. 1991. T cell proliferation induced by *Borrelia burgdorferi* in patients with Lyme borreliosis. Autologous serum required for optimum stimulation. *Arthritis Rheum* 34:393-402.
346. Horneff, G., F. Emmrich, J. R. Kalden, and G. R. Burmester. 1991. [Suppression of monocyte-macrophage activation by anti-CD4 therapy in patients with chronic polyarthritis]. *Immun Infekt* 19:55-56.
347. Horneff, G., W. Becker, F. Wolf, J. R. Kalden, and G. R. Burmester. 1991. [Human anti-murine immunoglobulin antibodies as disturbing factors in TSH determination]. *Klin Wochenschr* 69:220-223.
348. Alsalameh, S., B. Jahn, A. Krause, J. R. Kalden, and G. R. Burmester. 1991. Antigenicity and accessory cell function of human articular chondrocytes. *J Rheumatol* 18:414-421.
349. Krause, A., A. Rensing, J. R. Kalden, and G. R. Burmester. 1991. Cellular immune response to *Borrelia burgdorferi* in patients with Lyme borreliosis. *Behring Inst Mitt*:52-58.
350. Burmester, G. R., U. Altstidl, J. R. Kalden, and F. Emmrich. 1991. Stimulatory response towards the 65 kDa heat shock protein and other mycobacterial antigens in patients with rheumatoid arthritis. *J Rheumatol* 18:171-176.
351. Horneff, G., G. R. Burmester, F. Emmrich, and J. R. Kalden. 1991. Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. *Arthritis Rheum* 34:129-140.
352. Keyna, U., I. Nusslein, P. Rohwer, J. R. Kalden, and B. Manger. 1991. The role of the transferrin receptor for the activation of human lymphocytes. *Cell Immunol* 132:411-422.
353. Emmrich, F., G. Horneff, W. Becker, W. Luke, A. Potocnik, U. Kanzy, J. R. Kalden, and G. Burmester. 1991. An anti-CD4 antibody for treatment of chronic inflammatory arthritis. *Agents Actions Suppl* 32:165-170.
354. Nusslein, H. G., M. Winter, T. Trag, and J. R. Kalden. 1991. Interleukin-4-induced IgG subclass and IgE secretion by mononuclear cells from atopic donors. *Int Arch Allergy Appl Immunol* 95:257-260.
355. Hartung, K., R. Coldewey, E. Rother, K. Pirner, C. Specker, H. H. Peter, J. R. Kalden, H. J. Lakomek, H. Deicher, and G. G. de Lange. 1991. Immunoglobulin allotypes in systemic lupus erythematosus--results of a central European multicenter study. SLE Study Group. *Exp Clin Immunogenet* 8:11-15.
356. Kalden, J. R., T. Winkler, and F. Krapf. 1991. Are retroviruses involved in the aetiology of rheumatic diseases? *Br J Rheumatol* 30 Suppl 1:63-69.

357. Seuchter, S. A., M. Knapp, K. Hartung, R. Coldewey, J. R. Kalden, H. J. Lakomek, H. H. Peter, H. Deicher, and M. P. Baur. 1991. Testing for association in SLE families. *Genet Epidemiol* 8:409-416.
358. Kalden, J. R., T. H. Winkler, M. Herrmann, and F. Krapf. 1991. Pathogenesis of SLE: immunopathology in man. *Rheumatol Int* 11:95-100.
359. Oez, S., C. Buhner, J. Atzpodien, and J. R. Kalden. 1990. A highly sensitive quantitative bioassay for human granulocyte-macrophage colony-stimulating factor. *Exp Hematol* 18:1108-1111.
360. Pirner, K., W. Rosler, J. R. Kalden, and B. Manger. 1990. [Long-term remission after i.v. immunoglobulin therapy in acquired antihemophilic factor hemophilia with systemic lupus erythematosus]. *Z Rheumatol* 49:378-381.
361. Valerius, T., R. Repp, J. R. Kalden, and E. Platzer. 1990. Effects of IFN on human eosinophils in comparison with other cytokines. A novel class of eosinophil activators with delayed onset of action. *J Immunol* 145:2950-2958.
362. Alsalameh, S., J. Mollenhauer, N. Hain, K. P. Stock, J. R. Kalden, and G. R. Burmester. 1990. Cellular immune response toward human articular chondrocytes. T cell reactivities against chondrocyte and fibroblast membranes in destructive joint diseases. *Arthritis Rheum* 33:1477-1486.
363. Harrer, T., B. Wolf, W. Kersten, W. Schwarz, D. Bergner, and J. R. Kalden. 1990. [HIV-1 antigenemia and T-cell activation in HIV-1 infected patients]. *Klin Wochenschr* 68:864-868.
364. Harrer, T., N. Hunzelmann, R. Stoll, A. Baur, and J. R. Kalden. 1990. Therapy for HIV-1-related nephritis with zidovudine. *Aids* 4:815-817.
365. Oez, S., H. Tittelbach, R. Fahsold, R. Schaetzel, C. Buhner, J. Atzpodien, and J. R. Kalden. 1990. Establishment and characterization of a granulocyte-macrophage colony-stimulating factor-dependent human myeloid cell line. *Blood* 76:578-582.
366. Oez, S., K. Welte, E. Platzer, and J. R. Kalden. 1990. A simple assay for quantifying the inducible adherence of neutrophils. *Immunobiology* 180:308-315.
367. Krapf, F. E., M. Herrmann, W. Leitmann, B. Schwartlander, and J. R. Kalden. 1990. Circulating immune complexes in HIV-infected persons. *Klin Wochenschr* 68:299-305.
368. Voll, R., C. Aepinus, F. Krapf, M. Herrmann, J. R. Kalden, and B. Fleckenstein. 1990. Monoclonal antibodies directed against the rev protein of human immunodeficiency virus type 1. *Mol Cell Probes* 4:63-72.
369. Becker, W., F. Emmrich, G. Horneff, G. Burmester, F. Seiler, A. Schwarz, J. Kalden, and F. Wolf. 1990. Imaging rheumatoid arthritis specifically with technetium 99m CD4-specific (T-helper lymphocytes) antibodies. *Eur J Nucl Med* 17:156-159.
370. Hain, N., S. Alsalameh, W. M. Bertling, J. R. Kalden, and G. R. Burmester. 1990. Stimulation of rheumatoid synovial and blood T cells and lines by synovial fluid and interleukin-2: characterization of clones and recognition of a co-stimulatory effect. *Rheumatol Int* 10:203-210.
371. Harrer, T., K. Messing, U. Bienzle, E. Meyer, J. Giedl, and J. R. Kalden. 1989. [Manifestation of AIDS in HIV infected homosexual males with lymphadenopathy syndrome]. *Klin Wochenschr* 67:936-939.

372. Sorg, C., and J. R. Kalden. 1989. Clinical research in the Federal Republic of Germany. *Immunol Today* 10:S6-7.
373. Kalden, J. R. 1989. Clinical autoimmunity. *Immunol Today* 10:S31-33.
374. Koch, B., W. Baum, G. R. Burmester, P. Rohwer, M. Reinke, J. Zacher, H. Kirchner, and J. R. Kalden. 1989. [Prostaglandin E₂, interleukin 1 and gamma interferon production of mononuclear cells of patients with inflammatory and degenerative joint diseases]. *Z Rheumatol* 48:194-199.
375. Krapf, F., M. Herrmann, W. Leitmann, and J. R. Kalden. 1989. Antibody binding of macromolecular DNA and RNA in the plasma of SLE patients. *Clin Exp Immunol* 75:336-342.
376. Huber, C., A. Ruger, M. Herrmann, F. Krapf, and J. R. Kalden. 1989. C3-containing serum immune complexes in patients with systemic lupus erythematosus: correlation to disease activity and comparison with other rheumatic diseases. *Rheumatol Int* 9:59-64.
377. Schulze-Lohoff, E., F. Krapf, L. Bleil, G. R. Burmester, K. Kolble, H. G. Nusslein, W. Rodl, and J. R. Kalden. 1989. IGM-containing immune complexes and antiphospholipid antibodies in patients with Sneddon's syndrome. *Rheumatol Int* 9:43-48.
378. Burmester, G. R., B. Jahn, N. Hain, G. Strobel, and J. R. Kalden. 1989. T cell regulation and T cell clones in relation to synovial inflammation. *Springer Semin Immunopathol* 11:259-272.
379. Krapf, F. E., M. Herrmann, W. Leitmann, and J. R. Kalden. 1989. Are retroviruses involved in the pathogenesis of SLE? Evidence demonstrated by molecular analysis of nucleic acids from SLE patients' plasma. *Rheumatol Int* 9:115-121.
380. Haupl, T., G. R. Burmester, G. Hahn, U. Feige, C. Rordorf-Adam, and J. R. Kalden. 1989. Differential immunological response of patients with rheumatoid arthritis towards two different Epstein-Barr virus strains: inhibition of interleukin-1 release by the B95-8, but not the P3HR-1 virus strain. *Rheumatol Int* 9:153-160.
381. Winkler, T. H., T. A. Henschel, I. Kalies, H. W. Baenkler, F. Skvaril, and J. R. Kalden. 1988. Constant isotype pattern of anti-dsDNA antibodies in patients with systemic lupus erythematosus. *Clin Exp Immunol* 72:434-439.
382. Krapf, F. E., B. J. Manger, and J. R. Kalden. 1988. [Churg-Strauss syndrome. Seldom seen or only seldom diagnosed?]. *Dtsch Med Wochenschr* 113:833.
383. Gramatzki, M., G. R. Burmester, H. J. Konig, F. Henschke, and J. R. Kalden. 1988. Synovial fluid involvement in null cell acute lymphoblastic leukemia diagnosed with monoclonal antibodies. *J Rheumatol* 15:500-504.
384. Fuchs, C., F. Krapf, P. Kern, S. Hoferichter, W. Jager, and J. R. Kalden. 1988. CEA-containing immune complexes in sera of patients with colorectal and breast cancer--analysis of complexed immunoglobulin classes. *Cancer Immunol Immunother* 26:180-184.
385. Hain, N., G. R. Burmester, and J. R. Kalden. 1988. T cell clones in rheumatoid arthritis (RA). *Scand J Rheumatol Suppl* 76:145-152.
386. Bonifacio, E., T. J. Cobain, R. L. Dawkins, M. Griffiths, J. R. Kalden, J. B. Peter, R. S. Tindall, and A. Vincent. 1988. Comparison and standardization of measurement of anti-acetylcholine receptor antibody between laboratories. *Autoimmunity* 1:59-66.

387. Platzer, E., S. Simon, and J. R. Kalden. 1988. Human granulocyte colony stimulating factor: effects on human long-term bone marrow cultures. *Blood Cells* 14:463-469.
388. Jahn, B., G. R. Burmester, P. Stock, P. Rohwer, and J. R. Kalden. 1987. Functional and phenotypical characterization of activated T cells from intra-articular sites in inflammatory joint diseases. Possible modulation of the CD3 antigen. *Scand J Immunol* 26:745-754.
389. Gohring, P. A., G. R. Burmester, and J. R. Kalden. 1987. Adhesion of human T lymphocytes to endothelial cells isolated from the umbilical vein: I. Similar binding patterns of normal and rheumatoid T cells. *Immunobiology* 175:385-393.
390. Burmester, G. R., G. F. Strobel, P. Gohring, and J. R. Kalden. 1987. Adhesion of human T lymphocytes to endothelial cells isolated from the umbilical vein: II. Enhanced binding of in vitro activated T lymphocytes. *Immunobiology* 175:394-405.
391. Harrer, T., K. Messing, U. Bienzle, E. Meyer, J. Giedl, and J. R. Kalden. 1987. [Follow-up in HIV-infected homosexual males with lymphadenopathy syndrome]. *Klin Wochenschr* 65:864-872.
392. Burmester, G. R., B. Jahn, P. Rohwer, J. Zacher, R. J. Winchester, and J. R. Kalden. 1987. Differential expression of Ia antigens by rheumatoid synovial lining cells. *J Clin Invest* 80:595-604.
393. Kalden, J. R. 1987. [Cytokines in tumor therapy]. *Onkologie* 10:240-244.
394. Nusslein, H. G., T. Zimmermann, M. Baum, C. Fuchs, K. Kolble, and J. R. Kalden. 1987. Improved in vitro diagnosis of allergy to *Alternaria tenuis* and *Cladosporium herbarum*. *Allergy* 42:414-422.
395. Kohleisen, B., I. Kalies, K. Kolble, and J. R. Kalden. 1987. Patient-specific heterogeneity of antinuclear antibodies as revealed by an isoelectric focusing immunoblot system. *Scand J Immunol* 26:71-78.
396. Gramatzki, M., G. R. Burmester, N. Heyder, H. G. Nusslein, W. Rodl, W. Grote, D. A. Monner, P. F. Muhlradt, and J. R. Kalden. 1987. Intralymphatic interleukin-2 treatment of a hemophiliac AIDS patient with defective interleukin-2 production. *Klin Wochenschr* 65:380-386.
397. Gramatzki, M., C. R. Bartram, D. Muller, M. Walter, H. Tittelbach, and J. R. Kalden. 1987. Early T cell differentiated chronic myeloid leukemia blast crisis with rearrangement of the breakpoint cluster region but not of the T cell receptor beta chain genes. *Blood* 69:1082-1086.
398. Platzer, E., and J. R. Kalden. 1987. Human granulocyte colony stimulating factor. *Blut* 54:129-136.
399. Kolble, K., V. Rukavina, and J. R. Kalden. 1987. High resolution electrophoresis for the allotyping of human C4. Proposal of a relational nomenclature. *J Immunol Methods* 96:69-76.
400. Nusslein, H. G., W. Rodl, J. Giedel, M. Missmahl, and J. R. Kalden. 1987. Multiple peripheral pulmonary nodules preceding rheumatoid arthritis. *Rheumatol Int* 7:89-91.
401. Kalden, J. R., and F. Krapf. 1987. [Pathomechanisms of tissue damage exemplified by collagenoses]. *Verh Dtsch Ges Inn Med* 93:93-97.

402. Kalden, J. R. 1987. [Immunology of the gastrointestinal system]. *Z Rheumatol* 46 Suppl 1:10-13.
403. Kalden, J. R. 1987. [Immunologic therapeutic approaches in malignant diseases, especially in pancreatic tumors]. *Verh Dtsch Ges Pathol* 71:266-270.
404. Jahn, B., G. R. Burmester, H. Schmid, G. Weseloh, P. Rohwer, and J. R. Kalden. 1987. Changes in cell surface antigen expression on human articular chondrocytes induced by gamma-interferon. Induction of Ia antigens. *Arthritis Rheum* 30:64-74.
405. Krapf, F., C. Fuchs, M. Herrmann, S. Hoferichter, and J. R. Kalden. 1986. Determination of complement activating circulating immune complexes and an example for antigen specific immune complex assays. *J Clin Lab Immunol* 21:183-187.
406. Platzer, E., S. Oez, K. Welte, A. Sendler, J. L. Gabrilove, R. Mertelsmann, M. A. Moore, and J. R. Kalden. 1986. Human pluripotent hemopoietic colony stimulating factor: activities on human and murine cells. *Immunobiology* 172:185-193.
407. Gramatzki, M., H. Nusslein, G. R. Burmester, W. Rodl, N. Heyder, W. Grote, D. A. Monner, P. F. Muhlratt, and J. R. Kalden. 1986. Intralymphatic interleukin 2 treatment in patients with acquired immunodeficiency syndrome: preliminary experience in three cases. *Immunobiology* 172:438-447.
408. Jonas, J., K. Kolble, H. E. Volcker, and J. R. Kalden. 1986. Central retinal artery occlusion in Sneddon's disease associated with antiphospholipid antibodies. *Am J Ophthalmol* 102:37-40.
409. Krapf, F. E., B. K. Manger, and J. R. Kalden. 1986. [Immune complexes in allergies: evidence of IgE-containing immune complexes in Churg-Strauss vasculitis]. *Klin Wochenschr* 64:563-569.
410. Jahn, B., G. R. Burmester, M. Gramatzki, G. Weseloh, P. Stock, and J. R. Kalden. 1986. Intraarticular T lymphocytes in monoarticular and oligoarticular inflammatory joint diseases. Normal subset distribution and less numbers of activated T cells indicate major differences as compared to rheumatoid arthritis. *J Rheumatol* 13:254-258.
411. Nusslein, H. G., M. Kleinlein, B. Hemmerlein, and J. R. Kalden. 1986. Different patterns of antigen-induced histamine release during immunotherapy in insect venom and pollen allergy. *Agents Actions* 18:248-250.
412. Nusslein, H. G., H. W. Baenkler, P. Stommer, W. Gruninger, M. Ulrich, F. Krapf, and J. R. Kalden. 1986. [Polyneuropathy in allergic granulomatosis and angiitis (Churg-Strauss syndrome)]. *Nervenarzt* 57:140-144.
413. Polke, C. R., J. W. Lowenthal, S. A. Roth, P. Rohwer, H. R. MacDonald, and J. R. Kalden. 1986. Phorbol ester enhances both interleukin 2 receptor expression and immunoglobulin secretion in human Epstein-Barr virus-immortalized B cells. *Eur J Immunol* 16:146-150.
414. Herbst, M., H. Fritz, H. G. Nusslein, B. J. Manger, J. R. Kalden, and R. Sauer. 1986. [Total lymphoid irradiation in chronic polyarthritis--a new therapeutic concept]. *Strahlenther Onkol* 162:25-30.
415. Roelcke, D., W. Dahr, and J. R. Kalden. 1986. A human monoclonal IgM kappa cold agglutinin recognizing oligosaccharides with immunodominant sialyl groups preferentially at the blood group M-specific peptide backbone of glycoporphins: anti-PrM. *Vox Sang* 51:207-211.

416. Burmester, G. R., M. Gramatzki, J. von Gernler, O. Bartels, and J. R. Kalden. 1985. Pulmonary sarcoidosis associated with acquired humoral and cellular immunodeficiency. *Clin Immunol Immunopathol* 37:406-412.
417. Bienzle, U., A. Rohr, R. Thomssen, K. Ritter, A. Uy, J. R. Kalden, J. Kalies, and I. Guggenmoos-Holzmann. 1985. Active immunization against hepatitis B: immunogenicity study in homosexual men. *Zentralbl Bakteriol Mikrobiol Hyg [A]* 260:403-410.
418. Nusslein, H. G., M. Herbst, B. J. Manger, M. Gramatzki, G. R. Burmester, H. Fritz, R. Sauer, and J. R. Kalden. 1985. Total lymphoid irradiation in patients with refractory rheumatoid arthritis. *Arthritis Rheum* 28:1205-1210.
419. Hohenberger, W., W. Haupt, J. R. Kalden, M. Simon, Jr., and J. Mahlstedt. 1985. [Autologous replantation of spleen particles--an established procedure? An opinion]. *Chirurg* 56:659-662.
420. Gramatzki, M., and J. R. Kalden. 1985. [Monoclonal antibodies in clinical diagnosis and therapy]. *Fortschr Med* 103:843-848.
421. Doldi, K., M. Leroux, H. Kirchner, U. Bienzle, K. Ritter, and J. R. Kalden. 1985. Proliferative responses to human cytomegalovirus in lymphocyte cultures of male homosexuals. *J Clin Lab Immunol* 17:111-114.
422. Manger, B. J., F. E. Krapf, M. Gramatzki, H. G. Nusslein, G. R. Burmester, P. B. Krauledat, and J. R. Kalden. 1985. IgE-containing circulating immune complexes in Churg-Strauss vasculitis. *Scand J Immunol* 21:369-373.
423. Krapf, F., B. Manger, B. Koch, P. Krauledat, and J. R. Kalden. 1985. The estimation of circulating immune complexes, C3d, and anti-ds-DNA-antibody serum levels in the monitoring of therapeutic plasmapheresis in a patient with systemic lupus erythematosus. A case report. *Clin Exp Rheumatol* 3:159-162.
424. Stock, K. P., G. R. Burmester, J. R. Kalden, H. Schmidt, and J. F. Riemann. 1985. [Immunologic and electron microscopic findings in an unusual case of Whipple's disease]. *Klin Wochenschr* 63:176-183.
425. Manger, B., M. Gramatzki, H. Nusslein, and J. R. Kalden. 1985. Coexistence of severe palmo-plantar Dupuytren's contracture, Raynaud's phenomenon and digital joint erosions. *Rheumatol Int* 5:95-96.
426. Low, A., A. Hotze, F. Krapf, W. Schranz, B. J. Manger, J. Mahlstedt, F. Wolf, and J. R. Kalden. 1985. The nonspecific clearance function of the reticuloendothelial system in patients with immune complex mediated diseases before and after therapeutic plasmapheresis. *Rheumatol Int* 5:69-72.
427. Koch, B., J. Giedl, P. Hermanek, and J. R. Kalden. 1985. The analysis of mononuclear cell infiltrations in colorectal adenocarcinoma. *J Cancer Res Clin Oncol* 109:142-151.
428. Krauledat, P. B., F. E. Krapf, B. Manger, and J. R. Kalden. 1985. Evaluation of plasma C3d and immune complex determinations in the assessment of disease activity of patients with rheumatoid arthritis, systemic lupus erythematosus, and spondylitis ancylopoetica. *Rheumatol Int* 5:97-101.
429. Kalden, J. R., and M. Gramatzki. 1985. [Immunologic methods]. *Verh Dtsch Ges Inn Med* 91:95-101.

430. Gramatzki, M., A. Schaaff, G. R. Burmester, B. Koch, A. H. Tulusan, and J. R. Kalden. 1985. Analysis of leukemic cells with monoclonal antibodies in acute myelomonocytic leukemia suggests abnormality at an early differentiation stage in certain cases. *Haematol Blood Transfus* 29:190-193.
431. Doldi, K., M. Leroux, R. Augustin, H. Kirchner, and J. R. Kalden. 1985. Proliferation and interferon production in whole blood samples and isolated lymphocyte preparations. *J Interferon Res* 5:55-64.
432. Kalies, I., F. Heinz, R. Hohlfeld, H. Wekerle, K. L. Birnberger, and J. R. Kalden. 1984. Physicochemical and immunological properties of acetylcholine receptors from human muscle. *Mol Cell Biochem* 64:69-79.
433. Burmester, G. R., B. Jahn, M. Gramatzki, J. Zacher, and J. R. Kalden. 1984. Activated T cells in vivo and in vitro: divergence in expression of Tac and Ia antigens in the nonblastoid small T cells of inflammation and normal T cells activated in vitro. *J Immunol* 133:1230-1234.
434. Gramatzki, M., W. Baum, G. R. Burmester, and J. R. Kalden. 1984. Preservation of the helper and suppressor/cytotoxic T-lymphocyte phenotype in continuous culture. *Eur J Immunol* 14:762-765.
435. Manger, B. J., R. Stix, E. Platzer, B. Hess, and J. R. Kalden. 1984. [Effect of histamine-blocking substances on mitogen-induced lympho proliferation in rheumatic diseases]. *Z Rheumatol* 43:175-178.
436. Nusslein, H. G., H. Jahn, G. Losch, I. Guggenmoos-Holzmann, W. Leibold, and J. R. Kalden. 1984. Association of HLA-Bw35 with mucocutaneous lesions in rheumatoid arthritis patients undergoing sodium aurothiomalate therapy. *Arthritis Rheum* 27:833-836.
437. Muller, D. S., B. Manger, R. Zawatzky, H. Kirchner, and J. R. Kalden. 1984. Mitogen-induced gamma interferon production in peripheral blood lymphocytes from patients with colorectal tumors. *Immunobiology* 166:494-499.
438. Schranz, W., and J. R. Kalden. 1984. [Treatment of immunologic diseases using plasma separation. Proven and unproved indications]. *Fortschr Med* 102:458-462.
439. Kalies, I., F. Heinz, W. P. Kaschka, K. F. Druschky, and J. R. Kalden. 1984. [Heterogeneity of acetylcholine receptor antibodies in patients with myasthenia gravis]. *Klin Wochenschr* 62:377-385.
440. Koch, B., W. Regnat, W. Solbach, R. Lanz, P. Hermanek, and J. R. Kalden. 1984. Interleukin-2 production in peripheral blood mononuclear cells of patients with gastrointestinal tumors. *J Clin Lab Immunol* 13:171-178.
441. Burmester, G. R., M. Gramatzki, A. Wirth, and J. R. Kalden. 1984. [Immunological characterization of unusual plasmacytic tumor cells in a disseminated non-Hodgkin's lymphoma]. *Immun Infekt* 12:107-108.
442. Doldi, K., B. Manger, B. Koch, J. Riemann, P. Hermanek, and J. R. Kalden. 1984. Spontaneous suppressor cell activity in the peripheral blood of patients with malignant and chronic inflammatory bowel diseases. *Clin Exp Immunol* 55:655-663.

443. Manger, B. J., G. R. Burmester, M. Grammatzki, H. Nusslein, U. Bienzle, and J. R. Kalden. 1984. Immunological studies in homosexual men with unexplained lymphadenopathy. *Eur J Clin Microbiol* 3:73-74.
444. Burmester, G. R., M. Grammatzki, H. K. Muller-Hermelink, W. Solbach, D. Djawari, and J. R. Kalden. 1984. Dissociation of helper/inducer T-cell functions: immunodeficiency associated with mycobacterial histiocytosis. *Clin Immunol Immunopathol* 30:279-289.
445. Koch, B., P. Locher, G. R. Burmester, W. Mohr, and J. R. Kalden. 1984. The tissue architecture of synovial membranes in inflammatory and non-inflammatory joint diseases. II. The localization of mononuclear cells as detected by monoclonal antibodies directed against T-lymphocyte subsets and natural killer cells. *Rheumatol Int* 4:79-85.
446. Burmester, G. R., J. Schneeberger, B. Jahn, M. Grammatzki, J. Zacher, and J. R. Kalden. 1984. Rheumatoid non-lymphoid synovial cells and the induction of mixed leukocyte reactions. Low-density preparations containing Ia+ macrophages and dendritic cells are less stimulatory than peripheral blood non-T cells. *Rheumatol Int* 4 Suppl:31-37.
447. Kalden, J. R. 1984. [Physiology and physiopathology of the immune system]. *Internist (Berl)* 25:3-10.
448. Kalden, J. R., G. R. Burmester, B. Manger, C. H. Coester, and U. Bienzle. 1983. [Immunologic findings in homosexual males with generalized lymphadenopathy. Prodromal state of acquired immunodeficiency syndrome?]. *Klin Wochenschr* 61:1067-1073.
449. Manger, B. F., R. Stix, A. L. Beck, and J. R. Kalden. 1983. Cimetidine and psoriatic arthritis. *Arch Dermatol* 119:792.
450. Kalden, J. R., O. Leitner, O. Klockel, H. Kirchner, B. Manger, and B. Koch. 1983. The autologous mixed lymphocyte reaction in patients with rheumatoid arthritis. *Behring Inst Mitt*:193-202.
451. Losch, G., F. Krapf, B. Manger, and J. R. Kalden. 1983. [Salicylic acid in the urine in recurrent stomach and duodenal ulcers?]. *Dtsch Med Wochenschr* 108:517-518.
452. Koch, B., W. Regnat, I. Schedel, H. Hermanek, W. Leibold, and J. R. Kalden. 1983. The binding of different lectins on peripheral blood mononuclear cells from patients with chronic inflammatory and malignant diseases. *Immunobiology* 164:99-109.
453. Burmester, G. R., P. Locher, B. Koch, R. J. Winchester, A. Dimitriu-Bona, J. R. Kalden, and W. Mohr. 1983. The tissue architecture of synovial membranes in inflammatory and non-inflammatory joint diseases. I. The localization of the major synovial cell populations as detected by monoclonal reagents directed towards Ia and monocyte-macrophage antigens. *Rheumatol Int* 3:173-181.
454. Kalden, J. R. 1982. Inflammation: crucial areas and clinical relevance. *Agents Actions Suppl* 11:15-24.
455. Kalden, J. R., W. Schranz, G. Losch, F. Krapf, and O. Bartels. 1982. [Recent developments in high-dose immunoglobulin therapy: therapeutic plasma exchange, autoimmune diseases]. *Beitr Infusionther Klin Ernahr* 9:48-59.
456. Manger, B., J. R. Kalden, R. Zawatzky, and H. Kirchner. 1981. Interferon production in the human mixed lymphocyte culture. *Transplantation* 32:149-152.

457. Beck, P., G. R. Burmester, A. Ledwoch, C. Urban, and J. R. Kalden. 1981. Autologous and allogeneic MLC-reactivity in patients with rheumatoid arthritis. *J Clin Lab Immunol* 6:27-33.
458. Hohlfeld, R., I. Kalies, F. Heinz, J. R. Kalden, and H. Wekerle. 1981. Autoimmune rat T lymphocytes monospecific for acetylcholine receptors: purification and fine specificity. *J Immunol* 126:1355-1359.
459. Burmester, G. R., P. Beck, R. Eife, H. H. Peter, and J. R. Kalden. 1981. Induction of a lymphotoxin-like mediator in peripheral blood and synovial fluid lymphocytes by incubation with synovial fluid from patients with rheumatoid arthritis. *Rheumatol Int* 1:139-143.
460. Wekerle, H., R. Hohlfeld, U. P. Ketelsen, J. R. Kalden, and I. Kalies. 1981. Thymic myogenesis, T-lymphocytes and the pathogenesis of myasthenia gravis. *Ann N Y Acad Sci* 377:455-476.
461. Gramatzki, M., and J. R. Kalden. 1981. Predominance of T-lymphocytes with a high-affinity receptor for sheep red blood cells in the synovial fluid of patients with rheumatoid arthritis. A short communication. *Z Rheumatol* 40:21-24.
462. Heinz, F., R. Pilz, S. Reckel, J. R. Kalden, and R. Haeckel. 1980. A new spectrophotometric method for the determination of 5'-nucleotidase. *J Clin Chem Clin Biochem* 18:781-788.
463. Schedel, I., P. C. Fink, W. Schoner, J. R. Kalden, H. H. Peter, and H. Deicher. 1980. Serum anti-immunoglobulins in multiple myeloma and benign monoclonal hyperglobulinemia. *Clin Immunol Immunopathol* 15:586-599.
464. Heinz, F., S. Reckel, R. Pilz, and J. R. Kalden. 1980. A new spectrophotometric assay for enzymes of purine metabolism. IV. Determination of adenosine deaminase. *Enzyme* 25:50-55.
465. Heinz, F., S. Reckel, R. Pilz, and J. R. Kalden. 1980. A new spectrophotometric assay for enzymes of purine metabolism. III. Determination of purine nucleoside phosphorylases. *Enzyme* 25:44-49.
466. Muller-Peddinghaus, R., J. R. Kalden, H. Meyer zu Schwabedissen, G. Trautwein, and S. Ueberschar. 1980. Immune complex glomerulonephritis of mink with Aleutian disease. *Contrib Nephrol* 19:101-103.
467. Muller-Peddinghaus, R., H. Meyer zu Schwabedissen, J. R. Kalden, G. Trautwein, and S. Ueberschar. 1980. Studies on the pathogenesis of Aleutian disease of mink. X. Demonstration of immune complexes by the 125I-C 1 q binding test after experimental infection. *Zentralbl Veterinarmed B* 27:1-10.
468. Kalden, J. R. 1979. [Functional tests of the immune system]. *Internist (Berl)* 20:465-474.
469. Kalies, I., J. R. Kalden, F. Heinz, R. W. Janzen, and L. Lachenmayer. 1979. [Demonstration of acetylcholine receptor antibodies in the serum of myasthenia gravis patients applying affinity chromatographically purified human acetylcholine receptor preparations (author's transl)]. *Klin Wochenschr* 57:875-881.
470. Heidenreich, W., K. Jagla, J. Schussler, P. Borner, F. Dehnhard, J. Deinhardt, J. Kalden, H. H. Peter, and H. Deicher. 1979. Immunological characterization of mononuclear cells and morphological findings in patients with mammary carcinoma. *J Cancer Res Clin Oncol* 95:65-74.
471. Pierschbacher, M. D., J. R. Kalden, and T. D. Luckey. 1979. In vitro induction of E-rosette formation in human bone marrow cells by the thymic proteins LSHr and LSHh. *Immunopharmacology* 1:315-321.

472. Heidenreich, W., K. Jagla, J. Schussler, P. Borner, F. Dehnhard, J. R. Kalden, W. Leibold, H. H. Peter, and H. Deicher. 1979. Immunological characterization of mononuclear cells in peripheral blood and regional lymph nodes of breast cancer patients. *Cancer* 43:1308-1313.
473. Heinz, F., S. Reckel, and J. R. Kalden. 1979. A new spectrophotometric assay for enzymes of purine metabolism. II. Determination of guanase activity. *Enzyme* 24:247-254.
474. Heinz, F., S. Reckel, and J. R. Kalden. 1979. A new spectrophotometric assay for enzymes of purine metabolism. I. Determination of xanthine oxidase activity. *Enzyme* 24:239-246.
475. Pierschbacher, M. D., T. D. Luckey, and J. R. Kalden. 1979. Biological activity of the pure thymus protein, LSHr. *Ann N Y Acad Sci* 332:49-54.
476. Gramatzki, M., and J. R. Kalden. 1978. The comparison of different rosette assay systems for the determination of T-lymphocytes in patients with solid malignant tumors. *Z Immunitätsforsch Immunobiol* 155:104-117.
477. Schaadt, M., V. Diehl, J. R. Kalden, N. Schmidt, and E. Laskewitz. 1978. [Long term effects of splenectomy on the immune-status of Hodgkin's disease patients depending on the modality of treatment (author's transl)]. *Med Klin* 73:1381-1388.
478. Schmidt, P., H. H. Peter, J. R. Kalden, H. J. Avenarius, and H. Bodenstein. 1978. [Effector function of acute leukemias in "spontaneous" (SCMC) and antibody dependent cellular cytotoxicity-tests (ADCC) (author's transl)]. *Klin Wochenschr* 56:953-962.
479. Siebert, F., J. R. Kalden, P. Fink, M. Fricke, and H. Deicher. 1978. The effect of serum and allogeneic antiglobulin preparations on the mitogenic reactivity of peripheral blood lymphocytes from patients with rheumatoid arthritis. *Z Rheumatol* 37:286-295.
480. Jagla, K., W. Heidenreich, J. Schussler, P. Borner, F. Dehnhard, H. Deicher, J. Kalden, and H. H. Peter. 1978. [Imprint cytology of axillary lymph nodes in breast neoplasms for intraoperative rapid diagnosis]. *Fortschr Med* 96:1366-1368.
481. Cesarini, J. P., R. Roubin, J. R. Kalden, and H. H. Peter. 1978. Human peripheral Nullymphocytes: ultrastructural aspects of the "K" cell effect against a melanoma target cell. *Biomedicine* 28:219-225.
482. Siewertsen, H. C., H. H. Peter, J. R. Kalden, J. Wusk, G. Eckert, S. Oehl, U. W. Schafer, and H. Deicher. 1978. Influence of continuous-flow blood separator leucophoresis on in vitro functions of human lymphocytes. *Clin Exp Immunol* 32:381-386.
483. Kalden, J. R. 1978. [LE diagnosis made easy]. *MMW Munch Med Wochenschr* 720:576.
484. Burmester, G. R., J. R. Kalden, H. H. Peter, I. Schedel, P. Beck, and A. Wittenborg. 1978. Immunological and functional characteristics of peripheral blood and synovial fluid lymphocytes from patients with rheumatoid arthritis. *Scand J Immunol* 7:405-417.
485. Kalden, J. R., B. Hoffken, and W. Stangel. 1977. Immune mechanism in gardner-diamond syndrome. *N Engl J Med* 297:1350.
486. Osterhage, F., M. Wippler, J. R. Kalden, and H. Deicher. 1977. Determination of specific IgE and IgG serum antibodies during immunotherapy in hay fever patients by RAST. *Z Immunitätsforsch Immunobiol* 153:189-203.

487. Kalden, J. R., H. H. Peter, R. Roubin, and J. P. Cesarini. 1977. Human peripheral Null lymphocytes. I. Isolation, immunological and functional characterization. *Eur J Immunol* 7:537-543.
488. Oehl, S., U. W. Schaefer, W. R. Boecker, J. R. Kalden, and H. H. Peter. 1977. Human peripheral blood "null-lymphocytes", a highly enriched pool for granulocytic stem cells (CFU-C). *Z Immunitätsforsch Immunobiol* 152:423-430.
489. Schedel, I., W. Schoner, R. Ziegler, J. R. Kalden, and H. Deicher. 1977. Idiotypic determinants and antiglobulins in multiple myeloma. *Haematol Blood Transfus* 20:329-332.
490. Kalden, J. R., H. Bodenstein, F. Friedrichs, M. Kissling, P. Troug, and H. von der Hardt. 1976. [Determination of colony stimulating activity in a child with cyclic neutropenia]. *Monatsschr Kinderheilkd* 124:485-487.
491. Bodenstein, H., J. R. Kalden, W. Friedrichs, M. Kissling, P. Troug, and H. von der Hardt. 1976. [Colony-stimulating activity in urine and serum in a child with cyclic neutropenia]. *Blut* 32:285-288.
492. Schedel, I., P. C. Fink, and J. Kalden. 1976. [Anti-immunoglobulins in multiple myeloma and benign monoclonal hyperglobulinemia]. *Blut* 32:275-278.
493. Diehl, V., K. Hegge, J. Kalden, U. Desselberger, and P. Krull. 1976. [Immunologic status in Hodgkin patients: correlation with Epstein-Barr virus titers]. *Blut* 32:279-284.
494. Peter, H. H., F. Knoop, and J. R. Kalden. 1976. Spontaneous and antibody-dependent cellular cytotoxicity in melanoma patients and healthy control persons. *Z Immunitätsforsch Exp Klin Immunol* 151:263-281.
495. Peter, H. H., R. F. Eife, and J. R. Kalden. 1976. Spontaneous cytotoxicity (SCMC) of normal human lymphocytes against a human melanoma cell line: a phenomenon due to a lymphotoxin-like mediator. *J Immunol* 116:342-348.
496. Kalden, J. R., I. Zimmer, and H. Deicher. 1976. [Significance of serum antibodies against dsDNA in the diagnosis of patients with systemic lupus erythematosus (proceedings)]. *Z Rheumatol* 35 Suppl 4:suppl 433-435.
497. Kalden, J. R., I. Zimmer, and H. Deicher. 1976. [Significance of serum antibodies against ds-DNA for diagnosis of patients with systemic lupus erythematosus]. *Verh Dtsch Ges Rheumatol* 4:433-435.
498. Kalden, J. R., E. Lohmann, H. H. Peter, and C. Hilger. 1976. Antibody-dependent cellular cytotoxicity and B- and T-cell activity in the peripheral blood of myasthenia gravis patients. *Ann N Y Acad Sci* 274:421-433.
499. Diehl, V., H. H. Peter, F. Knoop, D. Hille, and J. R. Kalden. 1976. Failure to immortalize human "null" cells by Epstein Barr virus (EBV) "in vitro". *Hamatol Bluttransfus* 19:471-473.
500. Kalden, J. R., H. H. Peter, E. Lohmann, J. Schedel, V. Diehl, and D. Vallee. 1976. Estimation of T- and K-cell activity in the peripheral blood of sarcoidosis patients. *Ann N Y Acad Sci* 278:52-68.
501. Kalden, J. R. 1975. [Immunologic methods in the differential diagnosis of collagen diseases]. *Med Welt* 26:2242-2247.

502. Kalden, J. R. 1975. [Auto-immune diseases of the skeletal muscle-system. Immune-pathogenetic mechanisms in myasthenia gravis and polymyositis (author's transl)]. *Immun Infekt* 3:100-115.
503. Arnold, W., J. R. Kalden, and H. von Mayersback. 1975. Influence of different histologic preparation methods on preservation of tissue antigens in the immunofluorescent antibody technique. *Ann N Y Acad Sci* 254:27-34.
504. Kalden, J. R., J. Brodehl, A. Kutz, P. Grob, and C. Hilger. 1975. [BCG granulomatosis, a complication of vaccination, induced through a limited cellular defect of the immune system]. *Monatsschr Kinderheilkd* 123:406-408.
505. Peter, H. H., J. R. Kalden, P. Seeland, V. Diehl, and G. Eckert. 1975. Humoral and cellular immune reactions 'in vitro' against allogeneic and autologous human melanoma cells. *Clin Exp Immunol* 20:193-207.
506. Fink, P. C., H. H. Peter, J. R. Kalden, H. Zeidler, and H. Deicher. 1975. [Quantitative determination of IgG-antiglobulins in the serum of patients with chronic polyarthritis and other disorders]. *Verh Dtsch Ges Inn Med* 81:1181-1182.
507. Kalden, J. R., H. H. Peter, J. Odriozola, W. Richter, and R. Richter. 1974. Letter: Sezary syndrome. *Lancet* 1:688.
508. Kalden, J. R., and T. O. Kleine. 1974. [Creatine-kinase-inhibiting factors in the serum of patients with myasthenia gravis]. *Verh Dtsch Ges Inn Med* 80:1650-1651.
509. Kalden, J. R. 1973. [Pathogenesis of partial neuromuscular block in experimental myasthenia gravis]. *Verh Dtsch Ges Inn Med* 79:588-589.
510. Kalden, J. R., W. G. Williamson, and W. J. Irvine. 1973. Experimental myasthenia gravis, myositis and myocarditis in guinea-pigs immunized with subcellular fractions of calf thymus or calf skeletal muscle in Freund's complete adjuvant. *Clin Exp Immunol* 13:79-88.
511. Becker, F. W., W. M. Gallmeier, C. Hertenstein, and J. R. Kalden. 1972. [Epstein-Barr-virus-antibodies and lymphocytotoxic serum-antibodies in patients with sarcoidosis]. *Klin Wochenschr* 50:927-928.
512. Pabst, R., H. Huchzermeyer, and J. Kalden. 1972. [Chlorpropamide therapy of diabetes insipidus]. *Med Klin* 67:462-465.
513. Muller, R., J. R. Kalden, B. Baruth, and H. Deicher. 1972. [Australia antigen in chronic aggressive hepatitis and liver cirrhosis. Its significance for the etiology and pathogenesis of chronic inflammatory liver diseases]. *Dtsch Med Wochenschr* 97:369-375.
514. Becker, F. W., P. Krull, H. Deicher, and J. R. Kalden. 1972. Leucocyte-migration test in sarcoidosis. *Lancet* 1:120-123.
515. Muller, R., J. Kalden, and H. Deicher. 1972. [Australia antigen and autoantibodies in chronic liver diseases]. *Verh Dtsch Ges Inn Med* 78:926-928.
516. Krull, P., F. K. Vykoupil, J. Kalden, and H. Deicher. 1972. [Burckhardt's iliac crest biopsy in visceral lupus erythematosus (correlations between morphology and clinical status)]. *Verh Dtsch Ges Inn Med* 78:870-872.

517. Kalden, J. R., and E. A. Guthy. 1972. Prolonged skin allograft survival in vitamin C-deficient guinea-pigs. Preliminary communication. *Eur Surg Res* 4:114-119.
518. Kalden, J. R., and K. James. 1971. The effect of anti-lymphocytic antibody on the development of experimental thyroiditis in rats induced by the intra-lymph node injection of rat thyroglobulin in Freund's complete adjuvant. *Immunology* 20:269-275.
519. Kalden, J. R., M. M. Evans, and W. J. Irvine. 1970. The effect of hypophysectomy on the immune response. *Immunology* 18:671-679.
520. Kalden, J. R. 1970. [Thymus pathology in diseases with disturbed immune reactions (review)]. *Z Immunitätsforsch Allerg Klin Immunol* 139:323-339.
521. Kalden, J. R., W. G. Williamson, and W. J. Irvine. 1970. The effect of thymectomy, hemi-thymectomy and sham thymectomy on experimental myasthenia gravis in guinea-pigs. *Clin Exp Immunol* 6:519-530.
522. Kalden, J. R. 1970. [The pathogenesis of myasthenia gravis as an immunological problem]. *Klin Wochenschr* 48:4-13.
523. Kalden, J., K. James, W. G. Williamson, and W. J. Irvine. 1969. The effect of anti-lymphocytic IgG on established autoallergic thyroiditis in rats. *Clin Exp Immunol* 5:597-606.
524. Kalden, J. R., W. G. Williamson, and W. J. Irvine. 1969. The effect of Bordetella pertussis vaccine on the development of experimental thyroiditis in rats immunized by the intra-lymph node route or into a hind footpad. *Clin Exp Immunol* 5:549-553.
525. Kalden, J. R., W. G. Williamson, R. J. Johnston, and W. J. Irvine. 1969. Studies on experimental autoimmune thymitis in guinea-pigs. *Clin Exp Immunol* 5:319-340.
526. Kalden, J. R., and W. J. Irvine. 1969. Experimental myasthenia gravis. *Lancet* 2:638-639.
527. Kalden, J., K. K. James, W. G. Williamson, and W. J. Irvine. 1968. The suppression of experimental thyroiditis in the rat by heterologous anti-lymphocyte globulin. *Clin Exp Immunol* 3:973-981.

B) Editorial activities and text-book contributions (since 1989):

1. J.R. Kalden.
Zelluläre Immunreaktivität. In: Labor und Diagnose.
(Ed. L. Thomas), Medizinische Verlagsgesellschaft Marburg, 575-591, 1984, and 4th Edition, 1992.
2. J.R. Kalden.
Immunologische Grundlagen Innerer Erkrankungen. In: Lehrbuch der Inneren Medizin (Ed. R. Gross, P. Scholmerich, W. Gerok) Schattauer Verlag, Stuttgart • New York, 33-48, 1987 and 1992
3. G.R. Burmester, J.R. Kalden
Monocytes in rheumatoid arthritis. In: Human monocytes (Ed. M. Zembala, G.L. Asherson),

Academic Press, 501-513, 1989

4. J.R. Kalden, B. Manger
Systemischer Lupus erythematodes. In: Rheumatologie in Praxis und Klinik (Ed. K. Fehr, W. Miehle, M. Schattenkirchner, K. Tillmann), Georg Thieme Verlag Stuttgart • New York 11.1-11.30, 1989
5. J.R. Kalden
Immunologie. In: Rheumatologie in Praxis und Klinik (Ed. K. Fehr, W. Miehle, M. Schattenkirchner, K. Tillmann) 3.1-1.14, Georg Thieme Verlag Stuttgart • New York, 1989.
6. Progress in Immunology Vol. VII, Proceedings of the 7th International Congress of Immunology Berlin 1989. (Ed. F. Melchers, E.D. Albert, H. v. Boehmer, M.P. Dierich, L. du Pasquier, K. Eichmann, D. Gemsa, O. Götze, J.R. Kalden, S.H.E. Kaufmann, H. Kirchner, K. Resch, G. Riethmüller, A. Schimpl, C. Sorg, M. Steinmetz, H. Wagner, H.G. Zachau), Springer Verlag Berlin Heidelberg • New York • London • Paris • Tokyo • Hong Kong, 1989
7. J.R. Kalden
Section Editor for "Autoimmunopathien und allergische Erkrankungen. In: Therapiehandbuch, 3rd Edition. (Ed. F. Krück, W. Kaufmann, H. Bünthe, E. Gladtko, R. Tölle), Urban & Schwarzenberg München - Wien - Baltimore 1989 und 1992
- 7a. J.R. Kalden, B. Manger
Systemischer Lupus erythematodes (SLE) und vaskulitische Syndrome, 1267-1272.
- 7b. J.R. Kalden
Immunsuppressive Therapie bei Autoimmunerkrankungen, 1273-1276.
- 7c. J.R. Kalden
Nekrotisierende Vaskulitiden, Riesenzell-Arteriitiden und Bindegewebserkrankungen, 1277-1282.
8. J.R. Kalden
Durch welche Mechanismen können Interferon-Gamma und andere Immunmodulatoren eine Gelenkdestruktion beeinflussen? In: Gelenkzerstörung bei entzündlichen rheumatischen Erkrankungen, Basismechanismen und deren Beeinflussung durch Therapie. (Ed. W. Mohr, K.H. Emmert), Steinkopff Verlag Darmstadt, 195-203, 1990
9. I.C. Kalies, J.R. Kalden
Neuroimmunologische Syndrome: Myasthenia gravis. In: Innere Medizin der Gegenwart, Klinische Immunologie (Ed. H.H. Peter), Urban & Schwarzenberg München - Wien - Baltimore, 452-461, 1991
10. E. Platzer, J.R. Kalden
Leukozytopenien und Agranulozytose. In: Innere Medizin in Praxis und Klinik, Band III: Blut und blutbildende Organe, Immunologie, Infektionen, Physikalische Einwirkungen. (Ed. H. Hornborstel, W. Kaufmann, W. Siegenthaler), 11.81-11.125, Georg Thieme Verlag Stuttgart • New York, 1991
13. Bayer Rheuma Workshop, Trends in RA-Research, Volume Editors: P. Hedqvist, Stockholm, J.R. Kalden, Erlangen, R. Müller-Peddinghaus, Cologne, D.R. Robinson, Boston, Fular Publishers,

Basel, Switzerland, 1991

12. D. Gemsa, J.R. Kalden, K. Resch (Editors)
Immunologie Grundlagen - Klinik - Praxis. Georg Thieme Verlag, Stuttgart, New York, 1991
- 12a. J.R. Kalden, S. Alsalameh
Diagnostik mit Hilfe immunologischer Methoden. In: Immunologie Grundlagen - Klinik - Praxis (Ed. D. Gemsa, J.R. Kalden, K. Resch), 232-247, Georg Thieme Verlag Stuttgart, New York, 1991
- 12b. J.R. Kalden
Gefäß- und Systemerkrankungen/Kollagenosen. In: Immunologie Grundlagen - Klinik - Praxis (Ed. D. Gemsa, J.R. Kalden, K. Resch), 419-439, Georg Thieme Verlag Stuttgart, New York, 1991
13. Molecular Biology Reports. An International Journal on Molecular and Cellular Biology. Special issue:
Molecular and Cell Biology of Autoantibodies and Autoimmunity. (Guest Ed. E.K.F. Bautz, J.R. Kalden, M. Homma, L.E. Shulman and E.M. Tan), Kluwer Academic Publishers, 15, Nos. 3/4, 1991
14. J.S. Smolen, J.R. Kalden, R.N. Maini (Editors)
Rheumatoid Arthritis, Recent Research Advances. Springer Verlag Berlin/Heidelberg/New York/London/Paris/Tokyo/Hong Kong/Barcelona/Budapest, 1992
- 14a. J.R. Kalden
Progress in the therapy of rheumatoid arthritis. In: Rheumatoid arthritis, Recent Research Advances (Ed. J.S. Smolen, J.R. Kalden, R.N. Maini), 365-385, Springer Verlag, Berlin/Heidelberg/New York/London/Paris/Tokyo/Hong Kong/Barcelona/Budapest, 1992
15. J.R. Kalden
Viral Arthritis. In: Rheumatology, Editors in chief: J.H. Klippel and P. Dieppe, Gower Medical Publishing, London, 6.1 - 6.2, 1994
16. S. Eger J.R. Kalden
Innere Medizin, Ed. G. Shettler, G. Greten. Immunologie internistischer Erkrankungen. Springer Verlag, Berlin/Heidelberg/New York/London/Paris/Tokyo/Hong Kong/Barcelona/Budapest, 1996
- 16a. S. Eger J.R. Kalden
Innere Medizin, Ed. G. Shettler, G. Greten. Immunologie internistischer Erkrankungen. Springer Verlag, Berlin/Heidelberg/New York/London/Paris/Tokyo/Hong Kong/Barcelona/Budapest. New edition 2005
17. J.R. Kalden, H. Klinger, D. Welzel (Editors)
Die Innere Medizin an der Schwelle des neuen Jahrhunderts. Forschungsperspektiven in den Schwerpunktfächern des neuen Jahrhunderts. Schattauer Verlag, Stuttgart/New York, 2000
18. J.R. Kalden (Guest editor)
Rheumatoid Arthritis. Current Challenges...Future Solutions. The Journal of Rheumatology, Symposium Proceedings (Suppl. 53)25, July 1998
19. J. R. Kalden (Guest Editor)
Changing the Course of Rheumatoid Arthritis. Proceedings from a satellite meeting held during EULAR '99. Scandinavian Journal of Rheumatology (Suppl. 112) 28, 1999

20. D. Furst, F.C. Breedveld, J. R. Kalden, J. S. Smolen (Guest Editors)
Advances in targeted therapies I. Ann Rheum Dis (Suppl. 1) 58, 1999
21. J. R. Kalden, J. S. Smolen (Guest Editors)
Challenges and Advances in Rheumatoid Arthritis (Based on the Proceedings of an International Conference held August 26-28, 1999 in Cannes). Rheumatology (Suppl. 1) 39, June 2000
22. F.C. Breedveld, J. R. Kalden, J. S. Smolen (Guest Editors)
Advances in targeted therapies II. Annals of the Rheumatic Diseases (Suppl. 1) 59, 2000
23. F.C. Breedveld, J. R. Kalden, J. S. Smolen (Guest Editors)
Advances in targeted therapies III. Annals of the Rheumatic Diseases (Suppl. 3) 60, 2001
24. G.R. Burmester, J. R. Kalden (Editors): Der IL-1-Rezeptor-Antagonist, Funktion und Stellenwert im Zytokinnetzwerk, Steinkopff Verlag, 1992
25. J.R. Kalden, M. Herrmann (Editors): Apoptosis and Autoimmunity from Mechanisms to Treatments,
Wiley-VHC Verlag, 2002
26. F.C. Breedveld, J.R. Kalden, J. S. Smolen (Editors): Advances in Targeted Therapies IV,
Supplement II, Annals of the Rheumatic Diseases, Vol. 61, Nov. 2002
27. St. Gay, J. R. Kalden (Editors): Molekulare Grundlagen von rheumatischen Erkrankungen, Springer Verlag Berlin/Heidelberg/New York, 2003
28. F.C. Breedveld, J.R. Kalden, J. S. Smolen (Editors): Advances in Targeted Therapies V,
Supplement II, Annals of the Rheumatic Diseases, Vol. 62, Nov 2003
29. F.C. Breedveld, J.R. Kalden, J. S. Smolen (Editors): Advances in Targeted Therapies VI,
Supplement II, Annals of the Rheumatic Diseases, Vol. 63, Nov 2004
30. F.C. Breedveld, J.R. Kalden, J. S. Smolen (Editors): Advances in Targeted Therapies VII,
Supplement II, Annals of the Rheumatic Diseases, Vol 64, Nov 2005